
<html lang="en"     class="pb-page"  data-request-id="76ec4738-4afc-43e5-b4d4-056762bfba97"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01652;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)" /></meta><meta name="dc.Creator" content="Hengmiao  Cheng" /></meta><meta name="dc.Creator" content="Suvi T. M.  Orr" /></meta><meta name="dc.Creator" content="Simon  Bailey" /></meta><meta name="dc.Creator" content="Alexei  Brooun" /></meta><meta name="dc.Creator" content="Ping  Chen" /></meta><meta name="dc.Creator" content="Judith G.  Deal" /></meta><meta name="dc.Creator" content="Yali L.  Deng" /></meta><meta name="dc.Creator" content="Martin P.  Edwards" /></meta><meta name="dc.Creator" content="Gary M.  Gallego" /></meta><meta name="dc.Creator" content="Neil  Grodsky" /></meta><meta name="dc.Creator" content="Buwen  Huang" /></meta><meta name="dc.Creator" content="Mehran  Jalaie" /></meta><meta name="dc.Creator" content="Stephen  Kaiser" /></meta><meta name="dc.Creator" content="Robert S.  Kania" /></meta><meta name="dc.Creator" content="Susan E.  Kephart" /></meta><meta name="dc.Creator" content="Jennifer  Lafontaine" /></meta><meta name="dc.Creator" content="Martha A.  Ornelas" /></meta><meta name="dc.Creator" content="Mason  Pairish" /></meta><meta name="dc.Creator" content="Simon  Planken" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Scott  Sutton" /></meta><meta name="dc.Creator" content="Luke  Zehnder" /></meta><meta name="dc.Creator" content="Chau D.  Almaden" /></meta><meta name="dc.Creator" content="Shubha  Bagrodia" /></meta><meta name="dc.Creator" content="Matthew D.  Falk" /></meta><meta name="dc.Creator" content="Hovhannes J.  Gukasyan" /></meta><meta name="dc.Creator" content="Caroline  Ho" /></meta><meta name="dc.Creator" content="Xiaolin  Kang" /></meta><meta name="dc.Creator" content="Rachel E.  Kosa" /></meta><meta name="dc.Creator" content="Ling  Liu" /></meta><meta name="dc.Creator" content="Mary E.  Spilker" /></meta><meta name="dc.Creator" content="Sergei  Timofeevski" /></meta><meta name="dc.Creator" content="Ravi  Visswanathan" /></meta><meta name="dc.Creator" content="Zhenxiong  Wang" /></meta><meta name="dc.Creator" content="Fanxiu  Meng" /></meta><meta name="dc.Creator" content="Shijian  Ren" /></meta><meta name="dc.Creator" content="Li  Shao" /></meta><meta name="dc.Creator" content="Feng  Xu" /></meta><meta name="dc.Creator" content="John C.  Kath" /></meta><meta name="dc.Description" content="The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kin..." /></meta><meta name="Description" content="The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 24, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01652" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01652" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01652" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01652" /></link>
        
    
    

<title>Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01652" /></meta><meta property="og:title" content="Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0019.jpeg" /></meta><meta property="og:description" content="The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer. A PI3Kα-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3Kα-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3S)-3-{[2′-amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1) (PF-06843195), with high PI3Kα potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of 1." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01652"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01652">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01652&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01652&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01652&amp;href=/doi/10.1021/acs.jmedchem.0c01652" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 644-661</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01197" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01671" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hengmiao Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengmiao Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#127a777c757f7b737d3c717a777c7552757f737b7e3c717d7f"><span class="__cf_email__" data-cfemail="7d1518131a10141c12531e1518131a3d1a101c1411531e1210">[email protected]</span></a>. Phone: 858-413-5668.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengmiao++Cheng">Hengmiao Cheng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1761-4503" title="Orcid link">http://orcid.org/0000-0003-1761-4503</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suvi T. M. Orr</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suvi T. M. Orr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#580b2d2e3176372a2a183f35393134763b3735"><span class="__cf_email__" data-cfemail="da89afacb3f4b5a8a89abdb7bbb3b6f4b9b5b7">[email protected]</span></a>. Phone: 858-284-7908.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suvi+T.+M.++Orr">Suvi T. M. Orr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Bailey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Bailey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Bailey">Simon Bailey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexei Brooun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexei Brooun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexei++Brooun">Alexei Brooun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ping Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ping Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Chen">Ping Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Judith G. Deal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Judith G. Deal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Judith+G.++Deal">Judith G. Deal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yali L. Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yali L. Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yali+L.++Deng">Yali L. Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin P. Edwards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin P. Edwards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+P.++Edwards">Martin P. Edwards</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary M. Gallego</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary M. Gallego</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary+M.++Gallego">Gary M. Gallego</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Grodsky</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Grodsky</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Grodsky">Neil Grodsky</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Buwen Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Buwen Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Buwen++Huang">Buwen Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mehran Jalaie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mehran Jalaie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mehran++Jalaie">Mehran Jalaie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Kaiser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Kaiser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Kaiser">Stephen Kaiser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert S. Kania</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert S. Kania</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kania">Robert S. Kania</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan E. Kephart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan E. Kephart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+E.++Kephart">Susan E. Kephart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer Lafontaine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Lafontaine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Lafontaine">Jennifer Lafontaine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martha A. Ornelas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martha A. Ornelas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martha+A.++Ornelas">Martha A. Ornelas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mason Pairish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mason Pairish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mason++Pairish">Mason Pairish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Planken</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Planken</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Planken">Simon Planken</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8901-8992" title="Orcid link">http://orcid.org/0000-0001-8901-8992</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Sutton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Sutton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Sutton">Scott Sutton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luke Zehnder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luke Zehnder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Zehnder">Luke Zehnder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chau D. Almaden</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chau D. Almaden</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chau+D.++Almaden">Chau D. Almaden</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shubha Bagrodia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shubha Bagrodia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shubha++Bagrodia">Shubha Bagrodia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew D. Falk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew D. Falk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+D.++Falk">Matthew D. Falk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hovhannes J. Gukasyan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hovhannes J. Gukasyan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hovhannes+J.++Gukasyan">Hovhannes J. Gukasyan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Caroline Ho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Caroline Ho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Caroline++Ho">Caroline Ho</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaolin Kang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaolin Kang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaolin++Kang">Xiaolin Kang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel E. Kosa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel E. Kosa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel+E.++Kosa">Rachel E. Kosa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ling Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Liu">Ling Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary E. Spilker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary E. Spilker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+E.++Spilker">Mary E. Spilker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sergei Timofeevski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sergei Timofeevski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sergei++Timofeevski">Sergei Timofeevski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ravi Visswanathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ravi Visswanathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ravi++Visswanathan">Ravi Visswanathan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenxiong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenxiong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenxiong++Wang">Zhenxiong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fanxiu Meng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fanxiu Meng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fanxiu++Meng">Fanxiu Meng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shijian Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shijian Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shijian++Ren">Shijian Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Shao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Shao">Li Shao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Xu">Feng Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">John C. Kath</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John C. Kath</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+C.++Kath">John C. Kath</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01652&amp;href=/doi/10.1021%2Facs.jmedchem.0c01652" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 644–661</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 24, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 September 2020</li><li><span class="item_label"><b>Published</b> online</span>24 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01652</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D644%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHengmiao%2BCheng%252C%2BSuvi%2BT.%2BM.%2BOrr%252C%2BSimon%2BBailey%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01652%26title%3DStructure-Based%2BDrug%2BDesign%2Band%2BSynthesis%2Bof%2BPI3K%25CE%25B1-Selective%2BInhibitor%2B%2528PF-06843195%2529%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D661%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01652"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2373</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01652" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hengmiao&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Suvi&quot;,&quot;last_name&quot;:&quot;T. M. Orr&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Bailey&quot;},{&quot;first_name&quot;:&quot;Alexei&quot;,&quot;last_name&quot;:&quot;Brooun&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Judith&quot;,&quot;last_name&quot;:&quot;G. Deal&quot;},{&quot;first_name&quot;:&quot;Yali&quot;,&quot;last_name&quot;:&quot;L. Deng&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;M. Gallego&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Grodsky&quot;},{&quot;first_name&quot;:&quot;Buwen&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Mehran&quot;,&quot;last_name&quot;:&quot;Jalaie&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Kaiser&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kania&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;E. Kephart&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Lafontaine&quot;},{&quot;first_name&quot;:&quot;Martha&quot;,&quot;last_name&quot;:&quot;A. Ornelas&quot;},{&quot;first_name&quot;:&quot;Mason&quot;,&quot;last_name&quot;:&quot;Pairish&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Planken&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Sutton&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Zehnder&quot;},{&quot;first_name&quot;:&quot;Chau&quot;,&quot;last_name&quot;:&quot;D. Almaden&quot;},{&quot;first_name&quot;:&quot;Shubha&quot;,&quot;last_name&quot;:&quot;Bagrodia&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;D. Falk&quot;},{&quot;first_name&quot;:&quot;Hovhannes&quot;,&quot;last_name&quot;:&quot;J. Gukasyan&quot;},{&quot;first_name&quot;:&quot;Caroline&quot;,&quot;last_name&quot;:&quot;Ho&quot;},{&quot;first_name&quot;:&quot;Xiaolin&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;E. Kosa&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;E. Spilker&quot;},{&quot;first_name&quot;:&quot;Sergei&quot;,&quot;last_name&quot;:&quot;Timofeevski&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;Visswanathan&quot;},{&quot;first_name&quot;:&quot;Zhenxiong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Fanxiu&quot;,&quot;last_name&quot;:&quot;Meng&quot;},{&quot;first_name&quot;:&quot;Shijian&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;C. Kath&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;644-661&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01652&quot;},&quot;abstract&quot;:&quot;The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer. A PI3Kα-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3Kα-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3S)-3-{[2′-amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1) (PF-06843195), with high PI3Kα potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of 1.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01652&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01652" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01652&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01652" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01652&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01652" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01652&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01652&amp;href=/doi/10.1021/acs.jmedchem.0c01652" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01652" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01652" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01652%26sid%3Dliteratum%253Aachs%26pmid%3D33356246%26genre%3Darticle%26aulast%3DCheng%26date%3D2021%26atitle%3DStructure-Based%2BDrug%2BDesign%2Band%2BSynthesis%2Bof%2BPI3K%25CE%25B1-Selective%2BInhibitor%2B%2528PF-06843195%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D644%26epage%3D661%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290838" title="Carbonyls">Carbonyls</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer. A PI3Kα-selective inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a PI3Kα-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds, exemplified by 2,2-difluoroethyl (3<i>S</i>)-3-{[2′-amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>1)</b> (PF-06843195), with high PI3Kα potency and unique PI3K isoform and mTOR selectivity were discovered. We describe here the details of the design and synthesis program that lead to the discovery of <b>1</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositide 3-kinases (“PI3Ks”) catalyze the synthesis of the phosphatidylinositol (“PI”) second messengers PI(3)P (“PIP”), PI(3,4)P<sub>2</sub> (“PIP<sub>2</sub>”), and PI(3,4,5)P<sub>3</sub> (“PIP<sub>3</sub>”).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The PI3K lipid kinase family is composed of eight enzymes categorized into three classes (I–III) based on sequence homology. Class I PI3Ks are further divided into class IA (PI3Kα, PI3Kβ, and PI3Kδ) and class IB (PI3Kγ). The PI3Kα and PI3Kβ isoforms are ubiquitously expressed, and it is suggested by several studies that PI3Kα is the predominant catalytic isoform engaged in glucose homeostasis regulation and in vasculogenesis, whereas PI3Kβ plays a secondary role in insulin signaling. In contrast, the PI3Kδ and PI3Kγ isoforms are primarily expressed in leukocytes and play important roles in immune response and inflammation.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Class I PI3Ks function as heterodimers, which are composed of a regulatory subunit associated with a catalytic subunit and catalyze the conversion of PIP<sub>2</sub> to PIP<sub>3</sub>. This conversion occurs in response to various extracellular triggers including activation of receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs). Synthesis of PIP<sub>3</sub> promotes downstream activation of AKT and mammalian target of rapamycin (mTOR), which influence several functions critical to cellular integrity including proliferation, evasion of apoptosis, metabolism, and angiogenesis. The PI3K/mTOR signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a></div><div class="NLM_p">Many inhibitors that target the PI3K/mTOR pathway with different selectivity profiles (i.e., PI3K/mTOR dual inhibitors, pan PI3K inhibitors, and PI3Kα-selective inhibitors) have progressed to clinical trials.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Limited efficacy has been reported for oral (PO) PI3K/mTOR dual inhibitors and pan PI3K inhibitors, as broad on-target toxicity prevented administration of a dose which suppressed the signaling pathway to an extent that could elicit significant efficacy.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> It was hypothesized that a selective PI3Kα inhibitor may provide the opportunity to spare patients the side effects associated with a broader inhibition of the class I PI3K family, therefore allowing greater suppression of the signaling pathway and durable antitumor efficacy.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Indeed, the PI3Kα-selective inhibitor alpelisib (<b>2</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was approved by the Food and Drug Administration (FDA) in 2019 to be used in combination with fulvestrant to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA-mutated advanced or metastatic breast cancer.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> In clinical trials, alpelisib demonstrated prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. Another PI3Kα-selective inhibitor, GDC-0077 (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), is currently in clinical development.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structurally diverse PI3Kα inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We describe here our efforts to discover an orally bioavailable PI3Kα-selective inhibitor by applying structure-based drug design (SBDD) and computational analysis. A novel series of compounds with high PI3Kα potency, unique PI3K isoform, and mTOR selectivity was discovered and are exemplified by 2,2-difluoroethyl (3<i>S</i>)-3-{[2′-amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>1</b>) (PF-06843195). The design and synthesis of these inhibitors are discussed in this manuscript.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Based on the hypothesis that targeting PI3Kα and sparing β and δ isoforms may enable greater inhibition of PI3Kα without toxicities from inhibiting other isoforms, our goal was to discover a compound with selectivity over these isoforms. Consequently, enzyme assays were developed to screen α, β, and δ activities and isogenic cellular assays were developed to evaluate the potency and selectivity of compounds in the cells.</div><div class="NLM_p">After a focused file-mining of internal<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> and external PI3K inhibitors,<a onclick="showRef(event, 'ref6 ref8 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref8 ref19 ref20 ref21">(6,8,19−21)</a> we decided to focus on a morpholine hinge binder, as it provided high kinome selectivity across protein kinases. A small fragment, compound <b>4</b>,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> was identified as our starting point with a very high ligand efficiency (LE = 0.70), PI3Kα <i>K</i><sub>i</sub> of 0.64 nM, moderate selectivity (24-fold) over β isoform, and good selectivity (128-fold) over δ isoform (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. DHPP Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">LE<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">PI3Kα <i>K</i><sub>i</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kβ <i>K</i><sub>i</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ <i>K</i><sub>i</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Log <i>D</i><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HLM CL<sub>intapp</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">RRCK<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">sol (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="char" char=".">258</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">N/D</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">210</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">368</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">–0.74</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">430</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">acetyl</td><td class="colsep0 rowsep0" align="char" char=".">410</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="left"><8</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">530</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">Me urea</td><td class="colsep0 rowsep0" align="char" char=".">425</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="left"><8</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">390</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Me carbamate</td><td class="colsep0 rowsep0" align="char" char=".">426</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left"><8</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Me sulfonyl</td><td class="colsep0 rowsep0" align="char" char=".">447</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="left"><8</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Me sulfamide</td><td class="colsep0 rowsep0" align="char" char=".">462</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="left"><11</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">380</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">LE = ligand efficiency.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Biological data with standard deviation and number of tests are included in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI2</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Log <i>D</i> = measured Log <i>D</i> at pH 7.4.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">HLM CL<sub>intapp</sub> = apparent intrinsic human liver microsomal clearance.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Passive permeability (<i>P</i><sub>app</sub> in 10<sup>–6</sup> cm/s) measured using low-efflux MDCKII cells.</p></div></div></div><div class="NLM_p">The crystal structure of <b>4</b> bound in PI3Kα was determined at a 2.9 Å resolution (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The oxygen atom in the morpholine ring formed a hydrogen bond with hinge residue Val851. The aminopyrimidine ring was tilted from the core pyrimidine by 13°, and the amino group formed a hydrogen-bond interaction with Asp805. There was also a hydrogen-bond interaction between catalytic Lys802 and one of the pyrimidine ring nitrogen atoms.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of <b>4</b> bound in PI3Kα (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71">7K71</a>). The yellow dashed lines indicate H-bond interactions, and the white dashed line indicates measured distance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To achieve isoform selectivity, we systematically analyzed the ATP binding sites for the α, β, δ, and γ isoforms, and identified three regions that could be used in our designs for selectivity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><div class="NLM_p">In region 1, Gln859 is a specific residue in PI3Kα and is not conserved within the PI3K family. At this location, isoforms β, δ, and γ have an aspartic acid, an asparagine, and a lysine residue, respectively. A hydrogen-bond interaction between ligand and Gln859 could yield isoform selectivity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">In region 2, a Trp residue is conserved within the PI3K family (Trp780 in PI3Kα). However, the orientation of the Trp indole ring in PI3Kβ is different from that in PI3Kα. In PI3Kα, the Trp780 indole ring NH points away from the G-loop, and in PI3Kβ, the Trp781 indole ring is rotated about 180°, with the NH group pointing toward the G-loop. This conformational difference could be utilized to design isoform selectivity over PI3Kβ.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a></div><div class="NLM_p">In region 3, Arg770 is a specific residue in PI3Kα and is not conserved within the PI3K family. At this location, isoforms β and γ have a lysine and δ has a threonine. Thr is shorter than Arg; hence, a ligand with a hydrogen-bond acceptor might selectively interact with Arg770 and not with Thr750, hence gaining isoform selectivity over PI3Kδ.</div><div class="NLM_p">There was a large unfilled space between the pyrimidine core of <b>4</b> and Gln859. We envisioned filling the space with a linker containing a terminal hydrogen-bond acceptor to interact with Gln859. Because the distance between the pyrimidine core in <b>4</b> and the terminal amide group in Gln859 is long (8.4 Å), we hypothesized that it would be critical to have a rigid linker to connect the core pyrimidine and the hydrogen-bond acceptor-containing group. Based on modeling studies and in silico calculated properties, linkers off a dihydropyrrolopyrimidine (DHPP) core were explored (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Computational modeling utilizing the crystal structure of <b>4</b> suggested that an (<i>S</i>)-pyrrolidine linker would optimally position the hydrogen-bond acceptor to interact with Gln859. DHPP derivative <b>5</b> with an (<i>S</i>)-pyrrolidine linker was prepared and tested. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>,  compound <b>5</b> exhibited good PI3Kα potency with a <i>K</i><sub>i</sub> of 2.1 nM.</div><div class="NLM_p">A set of DHPP compounds with hydrogen-bond acceptors attached to the (<i>S</i>)-pyrrolidine nitrogen atom were assembled, including an acetamide, a urea, a carbamate, a sulfonamide, and a sulfamide. These compounds demonstrated increased PI3Kα potency over <b>5</b> and robust absorption, distribution, metabolism and excretion (ADME) properties including HLM clearance, passive permeability, and solubility. Interestingly, all of the compounds exhibited the same LE as <b>5</b>. Compounds with sulfonyl groups showed stronger PI3Kα potency than those with carbonyl groups. For example, the acetamide derivative <b>6</b> exhibited PI3Kα <i>K</i><sub>i</sub> of 1.1 nM, 17-fold selectivity over β isoform, and 19-fold selectivity over δ isoform. The sulfamide derivative, <b>10</b>, showed a PI3Kα <i>K</i><sub>i</sub> of 0.12 nM, a 125-fold selectivity over β isoform, and a 37-fold selectivity over δ isoform. The DHPP compounds, in general, improved selectivity over β isoform but eroded selectivity over δ isoform compared with <b>4</b>. When tested in the cellular PI3Kα assay, <b>10</b> exhibited the highest activity with an IC<sub>50</sub> of 130 nM.</div><div class="NLM_p">To guide design efforts to further increase binding affinity, a co-crystal structure of <b>10</b> with PI3Kα protein was determined, and its binding mode is illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The morpholine oxygen atom formed a hydrogen-bond interaction with hinge residue Val851. The aminopyrimidine ring bound in the back pocket and was tilted from the DHPP core by 34°. The tilting of the pyrimidine ring was significantly greater than that in <b>4</b>, which may account for the decreased PI3Kδ selectivity for DHPP derivatives. The amino group formed a hydrogen-bond interaction with Asp805, and one of the pyrimidine ring nitrogen atoms interacted with Lys802. The (<i>S</i>)-pyrrolidine linker positioned the sulfamide oxygen atoms to form a hydrogen-bond network with both Gln859 in Region 1 and Arg770 in region 3, explaining the higher β isoform selectivity for compounds with sulfonyl groups than those with carbonyl groups. Examination of the binding mode revealed that a small hydrophobic pocket formed by Ile932 and Met922 side chains was not utilized, and there was significant strain energy (∼10 kcal/mol, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) associated with the bound conformation of <b>10</b>. One strategy to increase the binding affinity was to relieve the strain energy associated with the bound conformation while simultaneously filling the hydrophobic pocket. Gratifyingly, when a methyl group was modeled to substitute the (S)-hydrogen atom at the C(3) position of the pyrrolidine and fill the small hydrophobic pocket, the resultant compound <b>16</b> relieved conformational strain energy (∼3-fold) based on calculation using Batchmin V2.0 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>10</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O">7K6O</a>). The yellow dashed lines indicate H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Ligand Strain Energy Calculated by Batchmin 2.0 with Amber and OPLS2005 FF</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">strain type</th><th class="colsep0 rowsep0" align="center" char="±">mean strain for compound <b>10</b>, bound conformation in PI3Kα (kcal/mol)</th><th class="colsep0 rowsep0" align="center" char="±">mean strain for compound <b>16</b>, docked conformation in PI3Kα (kcal/mol)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">local</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">global</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 1.1</td></tr></tbody></table></div></div><div class="NLM_p">En route to the target compounds <b>12</b>–<b>19</b>, an <i>N</i>-<i>tert</i>-butylcarbamate (BOC) intermediate <b>11</b> was isolated and tested in both the enzyme and cell assays (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Interestingly, <b>11</b> demonstrated high PI3Kα potency in both the enzyme assay (<i>K</i><sub>i</sub> < 0.018 nM) and the cell assay (IC<sub>50</sub> = 6.8 nM). It also exhibited high selectivity over the PI3Kβ isoform (>1389-fold in the enzyme assay, 94-fold in the cell assay) and moderate selectivity over the PI3Kδ isoform (>26-fold in the enzyme assay, 14-fold in the cell assay).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of the DHPP Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0014.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0015.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>b</sup></sup><p class="last">Biological data with standard deviation and number of tests are included in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI2</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>c</sup></sup><p class="last">Log <i>D</i> = measured Log <i>D</i> at pH 7.4.</p></div><div class="footnote" id="t3fn3"><sup><sup>d</sup></sup><p class="last">HLM CL<sub>intapp</sub> = apparent intrinsic human liver microsomal clearance.</p></div><div class="footnote" id="t3fn4"><sup><sup>e</sup></sup><p class="last">Passive permeability (<i>P</i><sub>app</sub> in 10<sup>–6</sup> cm/s) measured using low-efflux MDCKII cells.</p></div><div class="footnote" id="t3fn5"><sup><sup>f</sup></sup><p class="last">LipE = lipophilic efficiency.</p></div></div><div></div></div><div class="NLM_p">The crystal structure of <b>11</b> bound in PI3Kα was determined (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The binding modes for the morpholine and aminopyrimidine were consistent with their binding modes in <b>10</b>. The C(3) methyl group filled the small hydrophobic pocket that was formed by Ile932 and Met922. The carbonyl oxygen atom of the carbamate group formed a hydrogen-bond interaction with Gln859, and the BOC group was positioned in a pocket near the hinge and interacted with the hydrophobic surface formed by Trp780. Computational studies indicated that the bound conformation for <b>11</b> was not the minimum-energy conformation, but this higher-energy conformation is stabilized by the hydrogen-bond interaction between carbamate carbonyl and Gln859.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>11</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a>). The yellow dashed lines indicate H-bond interactions. Hydrophobicity surface is shown for the binding site. The yellow color indicates hydrophobic surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For PI3Kβ, Asp860 is at the same location as Gln859 in PI3Kα. The distance between the carboxylate in Asp860 and the oxygen atom of the carbamate carbonyl in <b>11</b> was 5.4 Å. The peripheral carboxylate Asp was usually deprotonated; hence, it was not possible to form a hydrogen-bond interaction between Asp856 in PI3Kβ and the carbamate carbonyl in the ligand. In the absence of this hydrogen bond, the ligand bound in a minimum-energy conformation and the BOC group moved upward and clashed with Trp781 in PI3Kβ (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Figure SI1</a>).</div><div class="NLM_p">For PI3Kδ, the Asn836 at region 1 is too far away from the carbamate carbonyl to form a hydrogen bond. The lack of a hydrogen-bond interaction between Asn836 and the carbamate carbonyl can also explain the observed selectivity over PI3Kδ. As was previously discussed, the orientation of the region 2 Trp indole ring in PI3Kβ is different from that in PI3Kα and similar to PI3Kδ. In the minimum-energy conformation, the clash between the carbamate carbonyl in <b>11</b> and Trp781 in PI3Kβ was more severe than the clash with Trp760 in PI3Kδ; hence, greater selectivity was observed over PI3Kβ.</div><div class="NLM_p">With a measured Log <i>D</i> of 3.7, <b>11</b> demonstrated excellent permeability (Ralph Russ canine kidney (RRCK) = 16 × 10<sup>–6</sup> cm<sup>–1</sup>) and high human liver microsomal clearance (HLM Cl = 160 μL/min/mg). The design goal at this stage was to optimize the ADME properties, including lowering the clearance, while maintaining the potency and selectivity profile of <b>11</b>.</div><div class="NLM_p">A set of (<i>S</i>)-C(3)-methylpyrrolidine-containing DHPP compounds with the same distal hydrogen-bond acceptor groups as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were prepared and evaluated for PI3Kα potency and selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Comparing the pairs of compounds between (<i>S</i>)-pyrrolidines and (<i>S</i>)-C(3)-methyl pyrrolidines, the (<i>S</i>)-C(3)-methyl substitution significantly increased PI3Kα <i>K</i><sub>i</sub> and lipophilic efficiency (LipE).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> For example, with an acetamide, the (<i>S</i>)-C(3)-methyl derivative <b>12</b> increased PI3Kα <i>K</i><sub>i</sub> by 51-fold compared to <b>6</b>. The sulfamide derivative <b>16</b> increased PI3Kα <i>K</i><sub>i</sub> by >7-fold compared to <b>10</b>. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> illustrates the pairwise difference in PI3Kα <i>K</i><sub>i</sub> for (<i>S</i>)-pyrrolidines and (<i>S</i>)-C(3)-methyl pyrrolidines.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pairwise comparison of PI3Kα <i>K</i><sub>i</sub> for (<i>S</i>)-pyrrolidines (red) and (<i>S</i>)-C(3)-methyl pyrrolidines linker (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compared with <b>11</b>, the (<i>S</i>)-C(3)-methyl derivatives demonstrated decreased oxidative clearance and maintained excellent permeability and solubility. However, the cellular potency and isoform selectivity for the acetyl, methyl urea, carbamate, sulfonyl, and sulfamide derivatives were significantly lower than that for <b>11</b>. The reduction in both PI3Kα potency and isoform selectivity for these derivatives can be explained by the lack of bulkiness that contributed to both the PI3Kα potency and isoform selectivity for <b>11</b>.</div><div class="NLM_p">The focus shifted to identifying sterically similar groups to the bulky BOC group of <b>11</b> to achieve similar PI3Kα potency and isoform selectivity, such as the last three entries in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Isopropylcarboxamide derivative <b>17</b> exhibited high PI3Kα cellular potency (cell IC<sub>50</sub> = 7 nM), excellent permeability (RRCK = 36 × 10<sup>–6</sup> cm<sup>–1</sup>), excellent solubility, and 37-fold cellular selectivity over PI3Kβ isoform. However, <b>17</b> exhibited only 3-fold cellular selectivity over PI3Kδ and high microsomal clearance (HLM = 46 μL/min/mg). Introduction of a tertiary hydroxyl group to the isopropyl methine position in <b>17</b> provided compound <b>18</b> with lowered Log <i>D</i> and consequently lower oxidative clearance, as well as a loss in PI3Kα potency with a cell IC<sub>50</sub> = 53 nM. Substitution of the hydroxyl group of <b>18</b> with an amino group provided compound <b>19</b> demonstrating promising overall properties; PI3Kα cell IC<sub>50</sub> = 25 nM, 13-fold cell selectivity over PI3Kβ, 5-fold cell selectivity over PI3Kδ, excellent solubility, low oxidative clearance, and moderate permeability. Based on its overall in vitro profile, <b>19</b> was selected for in vivo mouse pharmacokinetic (PK) and PK/pharmacodynamic (PD) studies. Unfortunately, low oral absorption and significant exposure variation between animals were observed.</div><div class="NLM_p">Dihydropyrrolopyrimidines (DHPPs) were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Reaction of 1,3,2-dioxathiolane 2,2-dioxide (<b>21</b>)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with 2-morpholino-4,6-dichloropyrimidine (<b>20</b>) in the presence of <i>n</i>-butyllithium furnished <b>22</b>, which then underwent an SNAr reaction with aminopyrrolidine <b>23</b>. Subsequent mesylation of <b>24</b> and base-mediated ring closure provided the DHPP scaffold <b>25</b>. Suzuki coupling of <b>25a</b> and <b>25b</b> with boronate <b>26</b> gave <b>27</b> and <b>11</b>, respectively, which were then subjected to acid-mediated BOC group removal. The resultant pyrrolidine NH group underwent amide, sulfonamide, urea, sulfamide, or carbamate formation, providing compounds <b>6</b>–<b>10</b> and <b>12</b>–<b>19</b>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dihydropyrrolopyrimidine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) <i>n</i>BuLi, tetrahydrofuran (THF); 6 N HCl, 83%; (b) diisopropylethylamine (DIEA), <i>N</i>-methylpyrrolidine (NMP), 130 °C (R<sup>1</sup> = H: ∼50%, R<sup>1</sup> = Me: 80%); (c) (i) MsCl, Et<sub>3</sub>N, dimethylaminopyridine (DMAP), dichloromethane (DCM), 0 °C to room temperature (RT); (ii) <i>N</i>,<i>N</i>′-dimethylformamide (DMF), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 55–80 °C (R<sup>1</sup> = H: 78% over two steps, R<sup>1</sup> = Me: 90% over two steps); (d) R<sup>1</sup> = H: Pd(dppf)Cl<sub>2</sub>, CsF, dioxane, water, 100 °C, microwave, 87%; R<sup>1</sup> = Me: Pd(dppf)Cl<sub>2</sub>, NaHCO<sub>3</sub>, dioxane, water, 130 °C, microwave, 80%; (e) HCl, dioxane, RT (R<sup>1</sup> = H, >99%, R<sup>1</sup> = Me, >99%); (f) R<sup>3</sup>–X; see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Supporting Information</a>.</p></p></figure><div class="NLM_p">It is worth noting that after step d, the DHPP core becomes sensitive to light-mediated degradation and all reactions are recommended to be carried out in foil-covered vessels and final products stored in amber bottles. By liquid chromatography–mass spectrometry (LCMS) and <sup>1</sup>H NMR, aromatization of the dihydropyrrole to pyrrole was observed.</div><div class="NLM_p">The DHPP scaffold exhibited significant challenges to balance potency, selectivity, and ADME properties to achieve orally bioavailable molecules. In this series, a high Log <i>D</i> was required to achieve sufficient PI3Kα activity. However, high lipophilicity also came with high oxidative clearance. Log <i>D</i> was lowered by introduction of polar groups such as an alcohol or an amine, allowing lower oxidative clearance but with a loss in passive permeability and decreased cellular PI3Kα potency. In addition, DHPP analogues were sensitive to oxidation in the presence of light. These collective challenges inspired a search for an alternative scaffold to which our learnings could be applied.</div><div class="NLM_p">With this goal in mind, our focus was shifted to a pyrimidine core. En route to these new, less rigid pyrimidine analogues, the BOC derivative <b>28</b> with (<i>S</i>)-C(3)-methylpyrrolidine was prepared and evaluated in key assays (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Light sensitivity was not observed for <b>28</b> as it was for <b>11</b>. Pyrimidine <b>28</b> also exhibited higher solubility than <b>11</b>, but the cellular PI3Kα potency was significantly lower a 16-fold drop.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Comparison of BOC Derivatives in the DHPP and Pyrimidine Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0016.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd ID</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kα <i>K</i><sub>i</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kβ <i>K</i><sub>i</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ <i>K</i><sub>i</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Rat1α IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Rat1β IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Rat1δ IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Log <i>D</i><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM CL<sub>intapp</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">RRCK<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char=".">Sol (μM)</th><th class="colsep0 rowsep0" align="center" char=".">LipEe (Rat1α IC<sub>50</sub>)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">640</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">160</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">0.095</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">5000</td><td class="colsep0 rowsep0" align="char" char=".">460</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="."><0.018</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">4600</td><td class="colsep0 rowsep0" align="char" char=".">1,200</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">460</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Biological data with standard deviation and number of tests are included in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI2</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Log <i>D</i> = measured Log <i>D</i> at pH 7.4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">HLM CL<sub>intapp</sub> = apparent intrinsic human liver microsomal clearance.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Passive permeability (<i>P</i><sub>app</sub> in 10<sup>–6</sup> cm/s) measured using low-efflux MDCKII cells.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">LipE = lipophilic efficiency.</p></div></div></div><div class="NLM_p">To identify options to increase PI3Kα potency, <b>28</b> was modeled in the binding site of PI3Kα protein by maintaining the key hydrogen-bond interactions including those between morpholine and hinge residue Val851, the carbamate carbonyl and Gln859, and the hydrogen-bond interactions of aminopyrimidine with Asp805 and Lys802 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The pyrrolidine (<i>S</i>)-3(C)-methyl group filled the small hydrophobic pocket formed by Ile932 and Met922. The methyl group was also pointing toward the backbone carbonyl of Ser919 with a 4.5 Å distance. It was hypothesized that changing the (<i>S</i>)-3(C)-methyl group to a hydroxymethyl group would introduce a hydrogen-bond interaction to the carbonyl group of Ser919. Consequently, the (<i>S</i>)-3(C)-hydroxymethyl pyrrolidine compound <b>29</b> was prepared. Promising overall properties were observed, with PI3Kα <i>K</i><sub>i</sub> < 0.018 nM (below the assay limit of detection), high enzyme isoform selectivity (>3000-fold over PI3Kβ, >116-fold over PI3Kδ), good cell isoform selectivity (100-fold over PI3Kβ, 26-fold over PI3Kδ), excellent permeability (RRCK = 18 × 10<sup>–6</sup> cm<sup>–1</sup>), and moderate kinetic solubility (46 μM). As expected with the lipophilic BOC group in <b>29</b>, the microsomal clearance was high (HLM Cl = 140 μL/min/mg) and hence more polar replacements were investigated.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Modeled bound conformation of 28 based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a>. The yellow dashed lines indicate H-bond interactions and the white dashed line indicates measured distance. The electrostatic potential surface is shown for the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The BOC group in <b>29</b> is highly lipophilic and contributes to high oxidative clearance, just like in <b>11</b>. To optimize the ADME properties, we decided to investigate metabolically stable alternatives to the BOC group (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compared to the pairs from the DHPP series, both the isopropylcarboxamide and methyl sulfonyl compounds (<b>30</b> and <b>32</b>) lost PI3Kα potency (<i>K</i><sub>i</sub> = 0.14 nM, >7.5-fold, and <i>K</i><sub>i</sub> = 0.3 nM, >17-fold, respectively). It is worth noting that the passive permeability for both <b>30</b> and <b>32</b> was very low (RRCK of 0.19 and 0.23 cm<sup>–1</sup>, respectively) having a negative impact on the cellular potency (PI3Kα IC<sub>50</sub> of 1100 and 1300 nM, respectively). The methyl carbamate derivative <b>31</b> demonstrated low oxidative clearance (HLM Cl = 13 μL/min/mg) and moderate PI3Kα cell potency (IC<sub>50</sub> = 91 nM). However, the permeability for <b>31</b> was low (RRCK = 1 cm<sup>–1</sup>). Interestingly, the difluoroethyl carbamate derivative <b>33</b> exhibited increased permeability and cell potency with RRCK of 3.9 × 10<sup>–6</sup> cm<sup>–1</sup> and cell IC<sub>50</sub> of 53 nM. Further, <b>33</b> exhibited a similarly low oxidative clearance to <b>31</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Optimization of the Pyrimidine Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0018.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>b</sup></sup><p class="last">Biological data with standard deviation and number of tests are included in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI2</a>.</p></div><div class="footnote" id="t5fn2"><sup><sup>c</sup></sup><p class="last">Log <i>D</i> = measured Log <i>D</i> at pH 7.4.</p></div><div class="footnote" id="t5fn3"><sup><sup>d</sup></sup><p class="last">HLM CL<sub>intapp</sub> = apparent intrinsic human liver microsomal clearance.</p></div><div class="footnote" id="t5fn4"><sup><sup>e</sup></sup><p class="last">Passive permeability (<i>P</i><sub>app</sub> in 10<sup>–6</sup> cm/s) measured using low-efflux MDCKII cells.</p></div><div class="footnote" id="t5fn5"><sup><sup>f</sup></sup><p class="last">LipE = lipophilic efficiency.</p></div></div><div></div></div><div class="NLM_p">To further increase PI3Kα potency, we evaluated the C(5) position of the pyrimidine core and found that fluorine substitution consistently provided approximately a 2-fold PI3Kα potency boost. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, the <i>K</i><sub>i</sub> value for both the methyl carbamate <b>34</b> and difluoroethyl carbamate <b>1</b> was <0.018 nM, and their PI3Kα cellular potency was approximately 2-fold improved relative to the corresponding C(5)–H pairs <b>31</b> and <b>33</b>. Compound <b>1</b> demonstrated cellular PI3Kα IC<sub>50</sub> potency of 18 nM and cellular isoform selectivity of 20-fold over PI3Kβ and 9-fold over PI3Kδ. Compound <b>1</b> was also evaluated in the mTOR cellular assay with cell IC<sub>50</sub> of 1.500 μM, corresponding to 83-fold cellular selectivity for PI3Kα vs mTOR.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> shows the co-crystal structure of <b>1</b> bound in PI3Kα. The oxygen atom in the morpholine ring formed a hydrogen bond with hinge residue Val851. The carbamate carbonyl formed a hydrogen bond with the side chain of the PI3Kα-specific residue Glu859. The aminopyrimidine group formed hydrogen-bond interactions with Lys802, Asp805, and Asp810 and interacted with Tyr836 through a conserved water molecule. The pyrrolidine (<i>S</i>)-C(3)-hydroxymethyl group interacted with Ser919, as designed, and indirectly interacted with Asn920 through a water molecule. The C(5)–F interacted indirectly with the Ala775 backbone carbonyl and the catalytic Lys802 through a water molecule. There was also a nonclassical hydrogen-bond interaction between CF<sub>2</sub>H and Ser854.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of <b>1</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M">7K6M</a>). The dashed lines represent H-bond interactions; yellow color indicates classical H-bond interactions, and blue color indicates a H bond between an activated C–H and a polar atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The isoform selectivity of <b>1</b> over PI3Kβ and PI3Kδ can be explained similarly to that for <b>11</b>. The ligand-bound conformation in PI3Kα was a high-energy conformation stabilized by the hydrogen bond between the carbamate carbonyl and Gln859. In the absence of this hydrogen bond, the ligand took up its minimum-energy conformation in PI3Kβ and PI3Kδ, resulting in clashes with Trp781 in PI3Kβ and Trp760 in PI3Kδ.</div><div class="NLM_p">Compound <b>1</b> also demonstrated high selectivity over mTOR, which was attributed to hinge residue Trp2239 at the location of Val851 in PI3Kα. Modeling studies suggest there was likely a severe clash between the Trp2239 side chain and the difluoroethyl carbamate group of <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Figure SI2</a>).</div><div class="NLM_p">Compounds in the pyrimidine series were prepared as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Dichloropyrimidines <b>20</b> and <b>35</b> underwent an nucleophilic aromatic substitution (SNAr) reaction with aminopyrrolidines <b>23b</b> or <b>36</b>, followed by a Suzuki coupling with boronate (<b>26</b>) to furnish <b>28</b>, <b>29</b>, and <b>38</b>. The BOC group of <b>38</b> was then cleaved, and the resultant amine was converted to amides, sulfonamides, ureas, sulfamides, or carbamates to provide compounds <b>30</b>–<b>34</b> and <b>1</b>. Alternatively, the BOC group of pyrrolidine <b>37c</b> could first be cleaved and the resultant amine was functionalized to afford <b>39</b>, then subjected to Suzuki reaction conditions to provide <b>1</b>. The former sequence was preferred for faster analogue synthesis and structure–activity relationship (SAR) exploration, whereas the latter was preferred for scale-up, mainly due to the lower solubility of intermediates containing the 2-aminopyrimidine group.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimidine Compounds<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>b</sup></span>Conditions: (a) DIEA, NMP, 70 °C (R<sup>1</sup> = Me, R<sup>2</sup> = H: 62%; R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F, 74%); (b); Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, water, 120 °C, 66% (R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F); (c) HCl, dioxane, >99%; (d) R<sup>3</sup>–X; see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Supporting Information</a>; (e) 2,2-difluoroethanol, carbonyldiimide (CDI), Et<sub>3</sub>N, DCM, 0 °C to RT, 77%; (f) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, <i>n</i>-butanol, water 100 °C; (R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F, 80%).</p></p></figure><div class="NLM_p">Compound <b>1</b> exhibited low oxidative clearance, high passive permeability, and a Log <i>D</i> of 1.9. The kinetic solubility for <b>1</b> was low (1.3 μg/mL at pH 7.4) as was thermodynamic solubility (6.2 μg/mL at pH 7.4) of a crystalline form. To improve the solubility of compound <b>1</b>, a phosphate ester prodrug strategy was explored. Compound <b>40</b> (PF-06862309) was subsequently prepared (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) and the aqueous kinetic solubility was dramatically improved (310 μg/mL at pH 7.4) as was thermodynamic solubility (6.2 mg/mL at pH 7.4) of a crystalline form.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Phosphate Ester Formation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Enzymatic hydrolysis of the phosphate ester <b>40</b> to the parent drug <b>1</b> in vitro was observed in the presence of purified human intestinal alkaline phosphatase. The enzymatic hydrolysis of <b>40</b> to <b>1</b> was further confirmed in intestinal S9 fractions of both rat (<i>t</i><sub>1/2</sub> = 86 min) and human (<i>t</i><sub>1/2</sub> = 14 min) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Figures SI3–SI6</a>). In addition, alkaline phosphatase was determined to be responsible for the hydrolysis of <b>40</b> in both rat and human intestinal S9 fractions by demonstrating the lack of hydrolysis of <b>40</b> in the presence of inorganic phosphate, a chemical inhibitor of alkaline phosphatase.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">Based on its overall in vitro properties, <b>1</b> was selected as a lead to progress to in vivo PK studies using an enhanced formulation (40% w/v captisol) along with its prodrug <b>40</b> formulated in phosphate-buffered saline (PBS, pH 7.4).</div><div class="NLM_p">The single-dose intravenous (IV) and oral (PO) pharmacokinetic (PK) studies of <b>1</b> and <b>40</b> in rats are presented in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Compound <b>1</b> exhibited a plasma clearance (CL<sub>p</sub>) of 30 mL/min/kg, a volume of distribution (<i>V</i><sub>ss</sub>) of 3 L/kg, and at 10 mg/kg, an oral bioavailability of 25%. The prodrug <b>40</b> exhibited high plasma clearance and negligible oral bioavailability (<1%). Plasma exposures of <b>1</b> in rats following administration of a single oral dose of 11.6 mg/kg of <b>40</b> (equivalent to 10 mg/kg of <b>1</b>) exhibited a similar oral plasma profile in rats dosed at orally with 10 mg/kg of <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Figure SI7</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mean PK Parameters of <b>1</b> and <b>40</b> in Male Wistar Han Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route and dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">compound dosed</th><th class="colsep0 rowsep0" align="center" char=".">compound measured</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>p</sub> (IV) (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">IV AUC<sub>o–<i>t</i></sub> (ng/(mL h))</th><th class="colsep0 rowsep0" align="center" char=".">PO AUC<sub>o–<i>t</i></sub> (ng/(mL h))</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV (2)</td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO (10)</td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1,400</td><td class="colsep0 rowsep0" align="char" char=".">330</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV (2.3)</td><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td><td class="colsep0 rowsep0" align="char" char=".">430</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">900</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO (11.6)</td><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1,500</td><td class="colsep0 rowsep0" align="char" char=".">290</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">These results showed that <b>40</b> was rapidly and quantitatively converted to <b>1</b> in vivo in the rat. The poor aqueous solubility of <b>1</b> resulted in limited absorption in a 1 day twice a day (BID) dose escalation rat toxicokinetic study of <b>1</b> (total daily PO dose between 50 and 500 mg/kg) in which plasma exposures (AUC 0–24 h) did not increase with dose. The substantially improved aqueous solubility of <b>40</b> coupled with the rapid and quantitative hydrolysis of the phosphate ester functional group resulted in a dose proportional increase in plasma exposures of <b>1</b> in a 1 day BID dose escalation rat toxicokinetic study at oral doses ranging from 50 to 500 mg/kg of <b>40</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Figure SI8</a>).</div><div class="NLM_p">In biochemical kinase assays, <b>1</b> was a potent inhibitor of both PI3Kα (<i>K</i><sub>i</sub> < 0.018 nM) and PI3Kδ (<i>K</i><sub>i</sub> < 0.28 nM) but found to be 9-fold selective for PI3Kα over PI3Kδ in cell assays (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). It was selective over two other members of the class I catalytic PI3K kinase group, PI3Kβ and PI3Kγ, >100- and >10 000-fold, respectively, in biochemical assays (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI1</a>) and 20-fold selective over PI3Kβ in cell assay (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Compound <b>1</b> proved to be a highly selective PI3Kα inhibitor when tested at 1 μM in a broad kinase panel (344 assays) at Life Technologies Corp. (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI1</a>). It was >1000-fold selective over the members of class 2 (PI3K-C2α, PI3K-C2β), class 3 (hVPS34), and class 4 (PI3Kα, PI4Kβ) groups of the PI3K family, PI3K-related (DNA-PK, mTOR) kinase family, all other protein kinases tested, and sphingosine kinases. Consistent with its high enzyme selectivity, <b>1</b> also exhibited high cellular selectivity (83-fold) over mTOR (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Cellular Potency Comparison between PF-06843195 and Alpelisib</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center">alpelisib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rat1 PI3Kα cell IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rat1 PI3Kβ cell IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">360 (20×)</td><td class="colsep0 rowsep0" align="left">3400 (17×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rat1 PI3Kδ cell IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">160 (9×)</td><td class="colsep0 rowsep0" align="left">510 (3×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR cell IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">1500 (83×)</td><td class="colsep0 rowsep0" align="left">3000 (15×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF7 pAKTT308 IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF7 proliferation IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">530</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T47D pAKT308 IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T47D proliferation IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">420</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Cellular data with standard deviation and number of tests are included in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Table SI3</a>.</p></div></div></div><div class="NLM_p">The comparison of cellular activities of <b>1</b> and alpelisib is shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. In the engineered RAT1 PI3K isoform cell lines, compared with alpelisib, <b>1</b> was 11-fold more potent against PI3Kα, similarly selective over PI3Kβ and more selective over PI3Kδ and mTOR. The breast cancer cell line MCF7 is characterized as ER<sup>+</sup>, HER2<sup>–</sup>, and harboring PIK3CA E542K mutation. Compared with alpelisib, <b>1</b> was 5-fold more potent in the MCF7 biomarker assay and 9-fold more potent in the MCF7 proliferation assay. The breast cancer cell line T47D is characterized as ER<sup>+</sup>, HER2<sup>–</sup>, and harboring PIK3CA-H1047R mutation. Compared with alpelisib, <b>1</b> was 3-fold more potent in the T47D biomarker assay and 13-fold more potent in the T47D proliferation assay.</div><div class="NLM_p">In the in vivo preclinical studies, <b>40</b>, as single agent, demonstrated robust PK/PD correlation and tumor growth inhibition (TGI) in mouse xenograft models with MDAMB361 and MCF7 cell lines. In double combination studies with fulvestrant or palbociclib, and in triple combination studies with both fulvestrant and palbociclib, tumor growth regression was observed in the MCF7 mouse xenograft model. The results from these PK/PD and TGI studies will be published in due course.</div><div class="NLM_p">The LipE development of the series discussed herein is summarized in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. For the DHPP series, compound <b>10</b> was the initial lead. Introduction of the (<i>S</i>)-3(C)-methyl on the pyrrolidine significantly increased PI3Kα potency as exemplified by the direct analogue <b>16</b> but without improvement in LipE. Compound <b>11</b> exhibited potent PI3Kα activity and high isoform selectivity but high metabolic clearance due to the high Log <i>D</i>. As a result, a BOC isostere strategy was pursued to lower Log <i>D</i> and maintain PI3Kα potency. Some notable examples are <b>14</b>, <b>17</b>, and <b>19</b>. From <b>11</b> to <b>19</b>, LipE increased 2.7 units. Compound <b>19</b> emerged as a new lead with good overall in vitro properties. Because of the significant in vivo exposure variation in rodents with <b>19</b>, the pyrimidine series was pursued while leveraging learnings from the DHPP series. The BOC-containing pyrimidine compound <b>28</b> was lacking in PI3Kα potency, compared to <b>11</b>. However, introduction of a (<i>S</i>)-3(C)-hydroxymethyl group led to <b>29</b>, with a LipE increase of 1.4 units. Optimization of <b>29</b> following the BOC isostere strategy led to compound <b>1</b>, with a LipE increase of 1.2 units.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. LipE summary for lead development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, through SBDD and computational analysis, a novel series of compounds with high PI3Kα potency, unique PI3K isoform selectivity, and mTOR selectivity profile were created. Compound <b>1</b> demonstrated excellent PI3Kα potency, good in vitro selectivity over PI3Kβ, moderate in vitro selectivity over PI3Kδ, and excellent selectivity over mTOR. Compound <b>1</b> also exhibited good metabolic stability and high permeability. The dose and solubility limited absorption of <b>1</b> were effectively addressed by converting it to the phosphate ester prodrug <b>40</b>. Based on the overall in vitro properties of <b>1</b>, and the overall in vivo results of <b>40</b>, it was nominated as a clinical candidate for treating breast cancer patients characterized with ER<sup>+</sup>, HER2<sup>–</sup>, and harboring PIK3CA mutations.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Synthetic Methods</h3><div class="NLM_p last">Starting materials and reagents were purchased from commercial suppliers and were used without further purification unless otherwise indicated. All reactions were performed under a positive pressure of nitrogen or argon or with a drying tube at ambient temperature in anhydrous solvents (unless otherwise stated). Reactions were monitored by liquid chromatography–mass spectrometry (LCMS) or thin-layer chromatography (TLC) and terminated as judged by the consumption of starting material. Microwave-assisted reactions were run in a Biotage Initiator. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument operating at 400 MHz unless otherwise indicated. <sup>1</sup>H NMR spectra were obtained as CDCl<sub>3</sub> or dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub> solutions (reported in parts per million (ppm)) and shifts reported relative to residual solvent signal (7.27 and 2.50 ppm, respectively) at 30 °C unless otherwise noted. Other NMR solvents were used as needed. <sup>13</sup>C NMR spectra were recorded at 101 MHz, and <sup>19</sup>F NMR spectra were recorded at 376 MHz. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad. Coupling constants, when given, are reported in hertz. Mass spectra were obtained using liquid chromatography–mass spectrometry (LCMS) on an Agilent 1260 LC with MSD Agilent model 6120 single-quadrupole mass spec detectors using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). High-resolution mass measurements were carried out on an Agilent high resolution mass 6230B with electrospray ionization source with an Agilent 6200 MassHunter TOF/Q-TOF version B.05.01. Preparative high-performance liquid chromatography (HPLC) conditions were as follows unless indicated otherwise: Agilent 1200 mass directed prep system A2P using automated purification software A.01.04; XBridge C18, 30 × 250 mm<sup>2</sup>, 5 μm particle size; column temperature, 60 °C; solvent A: water with 0.1% acetic acid; solvent B: acetonitrile with 0.1% acetic acid; flow rate, 80 mL/min; gradient: 5–30% B in 15 min, 30–95% B in 20 min, hold at 95% B for 5 min. All test compounds showed >95% purity as determined by combustion analysis or by LCMS. Combustion analyses were performed by Atlantic Microlab, Inc. (Norcross, GA).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Biochemical Assays</h3><div class="NLM_p">Recombinant human truncated PI3Kα (p110α/iSH2 p85α complex, designed to increase catalytic activity using truncated regulatory p85α subunit, amino acids 322–600), as well as full-length PI3Kα (p110α/p85α) were produced at Pfizer in-house as previously reported.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Full-length recombinant human PI3Kβ (p110β/p85α) and PI3Kδ (p110δ/p85α) were purchased from University of Dundee (Dundee, U.K.).</div><div class="NLM_p last">Biochemical kinase assays of PI3Kα, PI3Kβ, and PI3Kδ were conducted using a fluorescence polarization format similar to that previously reported.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The enzymatic reactions were conducted in 50 μL volumes in 96-well plates. The PI3Kα reactions contained 30 μM phosphatidylinositol 4,5-bisphosphate (“PIP2”) (Avanti Polar Lipids, Inc., Alabaster, AL), DMSO or test compound (12-point 3-fold serial dilution, 3 μM top dose, 2% DMSO final concentration), 5 mM MgCl<sub>2</sub>, 150 mM NaCl, 1 mM dithiothreitol (DTT), and 0.05% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (“CHAPS”) in 50 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES), pH 7.4, and were sonicated for 1 min prior to adding PI3Kα enzyme (2 nM full length or 0.5 nM truncated enzyme). The reactions were initiated by the addition of ATP (1 mM), following a 15 min preincubation. The reactions were incubated for 30 min at room temperature and stopped with ethylenediaminetetraacetic acid (EDTA), pH 8 (10 mM final concentration). In a detection plate, 15 μL of detector/probe mixture, containing 480 nM GST-Grp1PH domain protein (University of Dundee, Dundee, U.K.) and 12 nM carboxytetramethylrhodamine (TAMRA)-tagged fluorescent phosphatidylinositol (3,4,5)-triphosphate (PIP3) (Echelon Biosciences, Inc., Salt Lake City, UT) in assay buffer, was mixed with 15 μL of the kinase reaction mixture. The plate was shaken for 30 min, and fluorescence polarization values were measured on an LJL Analyst HT plate reader (Molecular Devices, Sunnyvale, CA). The assays for PI3Kβ (p110β/p85α) and PI3Kδ (p110δ/p85α) were conducted similarly to that described above for PI3Kα, using 5 nM PI3Kβ or 6.5 nM PI3Kδ (p110δ) and starting reactions by adding 60 μM ATP. The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies. The inhibition constants (<i>K</i><sub>i</sub>) were calculated by fitting fluorescence polarization values, corresponding to fractional initial velocities, using the tight-binding inhibition equation,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> applied for competitive inhibitors,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> using ActivityBase software (IDBS, Guildford, Surrey, U.K.) and experimentally determined apparent ATP <i>K</i><sub>m</sub> values of 41, 60, and 97 μM for PI3Kα, PI3Kβ, and PI3Kδ, respectively. The <i>K</i><sub>i</sub> values for PI3Kα, reported in this study, were generated using a more sensitive assay with truncated enzyme (p110α/iSH2 p85α). The <i>K</i><sub>i</sub> values for truncated and full-length PI3Kα were similar (data not shown).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Cell Lines and Cell Culture: Mechanistic Models</h3><div class="NLM_p last">To evaluate the isoform-specific potency of PI3KCA inhibitors in a cell-based system, an N-terminally myristoylated form of each PI3K class IA isoform was expressed in Rat1 fibroblasts. The plasmids contain human p110α, p110β, and p110δ with an N-terminal myristoylation (myr) signal and a flag-tag in C-terminal constructed by Biomiga, Inc. Successfully transfected Rat1 cells were selected and expanded and characterized for expression of the p110 isoforms.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> P-AKT(T308) Cellular Enzyme-Linked Immunosorbent Assay (ELISA)</h3><div class="NLM_p last">Engineered Rat1 myristoylated PI3K cells were seeded in 96-well plates at 4.0 × 10<sup>4</sup> (α/δ), 5.0 × 10<sup>4</sup> (β) cells/well in Roswell Park Memorial Institute (RPMI)-1640 medium with 10% fetal bovine serum (FBS), and incubated overnight. The cells were treated with compound at 10 mmol/L to 0.17 nmol/L in threefold serial dilutions and incubated for 2 h at 37 °C. The medium was removed, and the cells were lysed with 1× lysis buffer (Cell Signaling Technologies, 9803). Cell lysates were transferred to ELISA plates and the manufacturer’s instructions followed. ELISA kits were from Cell Signaling Technology: PathScan Phospho-AKT (Thr308) Sandwich ELISA Kit, 7135. P-AKT(T308) in MCF7 (ER<sup>+</sup>, HER2<sup>–</sup>, PIK3CA-E549K) and T47D (ER<sup>+</sup>, HER2<sup>–</sup>, PIK3CA-H1047R) were measured similarly.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> P-p70 S6(Thr389) Level of TSC1 Null Cells to Measure PI3K-Independent mTOR Activity</h3><div class="NLM_p last">In CellBind 96 well plate, 2.0 × 10<sup>4</sup> TSC1 null cells were seeded in RPMI-1640 with 10% FBS and incubated for 24 h. Then, the cells were replaced with serum-free medium and incubated overnight. After starvation, the cells were treated with compound at 10 mmol/L to 0.17 nmol/L in threefold serial dilutions and incubated for 2 h at 37 °C. The medium was discarded, and the cells were lysed. Cell lysates were transferred to ELISA plates, and the manufacturer’s instructions were followed. ELISA kits were from Cell Signaling Technology: PathScan Phospho-p70 S6 Kinase (Thr389) (CST#7153).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Cell Proliferation Assays</h3><div class="NLM_p last">MCF7 and T47D cells were plated at 2000 cell/well in 96-well culture plates in growth medium with 10% FBS. The cells were incubated overnight and treated with DMSO (0.1% final) or serially diluted for 7 days. CellTiter-Glo (Promega) was added to the cells. The plates were incubated at room temperature for 1 h, and luminescent signals were read. The IC<sub>50</sub> values were calculated by plotting fluorescence intensity versus drug concentration in nonlinear curves.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of <b>19</b></h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Step 1: Preparation of 2-[4,6-Dichloro-2-(morpholin-4-yl)pyrimidin-5-yl]ethanol (<b>22</b>)</h4><div class="NLM_p last">To a solution of 2-morpholino-4,6-dichloropyrimidine (<b>20</b>) (20 g, 85.4 mmol) in dry THF (650 mL) at −65 °C was dropwise added 2.5 M <i>n</i>-butyllithium in hexane (45 mL, 115.3 mmol), and the solution was stirred for 30 min. 1,3,2-Dioxathiolane 2,2-dioxide (<b>21</b>) (14.3 g, 115 mmol) was added at −65 °C, and stirring was continued for 1.5 h. The mixture was removed from dry ice bath, and 6 N aqueous HCl (300 mL) was added. The mixture was warmed to room temperature slowly, and stirring was continued for 18 h. The mixture was diluted with EtOAc (2 L), washed with water (2 × 500 mL), and saturated aqueous NaHCO<sub>3</sub> (2 × 500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluting with 3:1 petroleum ether/EtOAc) to give the title compound (20 g, 84%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.84 (t, <i>J</i> = 7.0 Hz, 2H), 3.80–3.76 (m, 4H), 3.76–3.72 (m, 4H), 3.04 (t, <i>J</i> = 7.0 Hz, 2H). LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>10</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> 277.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step 2: Preparation of <i>tert</i>-Butyl 3-{[6-Chloro-5-(2-hydroxyethyl)-2-(morpholin-4-yl)pyrimidin-4-yl]amino}-(<i>S</i>)-3-methylpyrrolidine-1-carboxylate (<b>24b</b>)</h4><div class="NLM_p last">To a solution of <b>22</b> (7.8 g, 28.0 mmol) and <i>tert</i>-butyl (3<i>S</i>)-3-amino-3-methylpyrrolidine-1-carboxylate (<b>23b</b>) (8.4 g, 42.1 mmol) in NMP (58 mL) was added diisopropylethylamine (24.5 mL, 140 mmol) at 15 °C, and the resulting mixture was heated to 130 °C and stirred at that temperature for 60 h. The mixture was diluted with EtOAc (100 mL) and washed with water (100 mL). The aqueous layer was extracted with EtOAc (2 × 100 mL). The combined organic layers were washed with brine (5 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 16 g of a brown gum. The crude product was purified by silica gel column chromatography eluting with a gradient of petroleum ether/EtOAc (20:1–8:1) to give the title compound (9.1 g, 73%) as a light yellow solid. LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>20</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>Cl 442.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step 3: Preparation of <i>tert</i>-Butyl (3<i>S</i>)-3-[4-Chloro-2-(morpholin-4-yl)-5,6-dihydro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl]-3-methylpyrrolidine-1-carboxylate (<b>25b</b>)</h4><div class="NLM_p last">To a stirring brown solution of <b>24b</b> (9.1 g, 20.59 mmol), triethylamine (8.49 mL, 61.8 mmol), and DMAP (252 mg, 2.06 mmol) in anhydrous DCM (125 mL) was dropwise added methanesulfonyl chloride (2.39 mL, 30.9 mmol) at 5–10 °C. The mixture was stirred at 15 °C for 3 h, then transferred to a separatory funnel and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 100 mL). The combined aqueous layers were extracted with DCM (100 mL). The combined organic phases were washed with brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give 10.6 g of a light yellow solid, which was dissolved in DMF (90 mL). DBU (9.03 mL, 60.4 mmol) was added, and the mixture was heated at 80 °C for 5 h. Water was added, and the mixture was extracted with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (5 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 9 g of a yellow gum. The gum was purified by silica gel column chromatography eluting with a gradient of petroleum ether/EtOAc (30:1–5:1) to give the title compound (7.5 g, 88%) as a white solid. LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>20</sub>H<sub>31</sub>N<sub>5</sub>O<sub>3</sub> 424.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Step 4: Preparation of <i>tert</i>-Butyl 3-[4-(2-Aminopyrimidin-5-yl)-2-(morpholin-4-yl)-5,6-dihydro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl]-(3<i>S</i>)-3-methylpyrrolidine-1-carboxylate (<b>11</b>)</h4><div class="NLM_p last">Two parallel reaction vessels containing a yellow mixture of <b>25b</b> (3.50 g, 8.256 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (<b>26</b>) (2.37 g, 10.7 mmol), and Na<sub>2</sub>CO<sub>3</sub> (2.63 g, 24.8 mmol) in 1,4-dioxane (90 mL) and water (30 mL) were prepared. To each reaction mixture was added Pd(dppf)Cl<sub>2</sub> (362 mg, 0.495 mmol) in one portion at 15 °C under nitrogen atmosphere, and the reaction mixtures were heated at 120 °C for 16 h. The mixtures were combined and concentrated to give 16 g of a black gum. The material was purified by silica gel column chromatography eluting with a gradient of 30–75% EtOAc in petroleum ether, followed by a gradient of 0–1% MeOH in EtOAc to give the title compound (7.0 g, 87%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 2H), 6.61 (br s, 2H), 3.80–3.63 (m, 11H), 3.54 (q, <i>J</i> = 8.7 Hz, 1H), 3.42–3.35 (m, 1H), 3.33–3.25 (m, 1H), 3.09 (t, <i>J</i> = 8.2 Hz, 2H), 2.44–2.35 (m, 1H), 2.07–2.00 (m, 1H), 1.42 (s, 9H), 1.32 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, a mixture of rotational isomers) δ 168.7, 163.3, 160.9, 157.3, 153.7, 150.5, 120.4, 104.9, 78.3, 66.0, 60.7, 60.2, 56.7, 55.9, 48.6, 46.2, 44.4, 43.0, 35.8, 28.5, 24.4, 17.7; LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>24</sub>H<sub>35</sub>N<sub>8</sub>O<sub>3</sub> 483.2 [M + H]<sup>+</sup>; HRMS: <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd for C<sub>24</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> 482.2754; found: 482.2759; OR: [α]<sub>D</sub><sup>22</sup> = −37.2° (<i>c</i> = 0.1, MeOH).</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step 5: Preparation of 5-{7-[(3<i>S</i>)-3-Methylpyrrolidin-3-yl]-2-(morpholin-4-yl)-6,7-dihydro-5<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}pyrimidin-2-amine Hydrochloride (<b>11i</b>)</h4><div class="NLM_p last">To a stirred yellow solution of <b>11</b> (5.60 g, 11.6 mmol) in DCM (30 mL) was added 4 M HCl in EtOAc (80 mL) dropwise at 0 °C and the solution was stirred at 10 °C for 2.5 h. The resultant yellow solids were collected by filtration, and the filter cake was dried under reduced pressure to give a yellow solid (6.5 g). The yellow solid was dissolved in water (50 mL) and lyophilized for 48 h to give the title compound (5.08 g, 88%) as a yellow gum. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.60–8.57 (m, 2H), 4.10 (d, <i>J</i> = 12.4 Hz, 1H), 3.88–3.70 (m, 10H), 3.54 (d, <i>J</i> = 12.5 Hz, 1H), 3.41 (t, <i>J</i> = 7.4 Hz, 2H), 3.03–2.98 (m, 2H), 2.63–2.55 (m, 1H), 2.24–2.17 (m, 1H), 1.47 (s, 3H); LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>19</sub>H<sub>27</sub>N<sub>8</sub>O 383.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Step 6: Preparation of <i>tert</i>-Butyl (1-{(3<i>S</i>)-3-[4-(2-Aminopyrimidin-5-yl)-2-(morpholin-4-yl)-5,6-dihydro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl]-3-methylpyrrolidin-1-yl}-2-methyl-1-oxopropan-2-yl)carbamate (<b>11ii</b>)</h4><div class="NLM_p last">To a mixture of <b>11i</b> (1.0 g, 1.77 mmol), 2-<i>tert</i>-butoxycarbonylamino-2-methyl-propionic acid (504 mg, 2.48 mmol), and diisopropylethylamine (2.16 mL, 12.4 mmol) in 10 mL of NMP was added 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU) (1.0 g, 2.67 mmol). The reaction was covered with foil and stirred at room temperature for 18 h. The reaction mixture was poured into aqueous NaHCO<sub>3</sub>, and the resulting precipitate was collected by filtration. The filtrate was extracted with DCM (three times). The filtrate and solids were combined, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography using a gradient of 0–10% MeOH/EtOAc to give the title compound (771 mg, 76%) as a foamy solid. <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 2H), 6.71–6.54 (m, 3H), 4.06–3.83 (m, 2H), 3.70–3.41 (m, 12H), 3.08 (t, <i>J</i> = 8.1 Hz, 2H), 2.47–2.35 (m, 1H, partially overlapped with DMSO), 2.10–2.01 (m, 1H), 1.39–1.28 (m, 18H); LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>28</sub>H<sub>42</sub>CN<sub>9</sub>O<sub>4</sub> 568.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Step 7: Preparation of 2-Amino-1-{(3<i><b>S</b></i>)-3-[4-(2-aminopyrimidin-5-yl)-2-(morpholin-4-yl)-5,6-dihydro-7<i><b>H</b></i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl]-3-methylpyrrolidin-1-yl}-2-methylpropan-1-one (<b>19</b>)</h4><div class="NLM_p last">In a foil-covered flask, a solution of <b>11ii</b> (369 mg, 0.65 mmol) in MeOH (3 mL) was treated with 4 N HCl in 1,4-dioxane (3 mL) and the mixture was stirred at room temperature for 18 h. The mixture was diluted with toluene and concentrated. The residue was dissolved in a minimum amount of MeOH, poured into saturated aqueous NaHCO<sub>3</sub>, and extracted with 15% <i>i</i>-PrOH in DCM (4×). The extracts were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The oily residue was suspended in a few milliliters of acetonitrile and sonicated briefly, inducing crystallization. The resulting solids were collected by filtration to give the title compound (206 mg, 68%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 2H), 6.68 (br s, 2H), 4.40–4.00 (m, 2H), 3.73–3.50 (m, 12H), 3.12–3.07 (m, 2H, partially overlapped with water), 2.41–2.30 (m, 1H), 2.06–1.97 (m, 1H), 1.74 (br s, 2H), 1.31 (s, 3H), 1.27 (s, 6H); LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>23</sub>H<sub>34</sub>CN<sub>9</sub>O<sub>2</sub> 468.3 [M + H]<sup>+</sup>; HRMS: <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd for C<sub>23</sub>H<sub>33</sub>N<sub>9</sub>O<sub>2</sub> 467.27572; found: 467.27642.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis of PF-06843195 (<b>1</b>)</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 1: Preparation of <i>tert</i>-Butyl (3<i>S</i>)-3-{[6-Chloro-5-fluoro-2-(morpholin-4-yl)pyrimidin-4-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>37c</b>)</h4><div class="NLM_p last">To a solution of 4-(4,6-dichloro-5-fluoropyrimidin-2-yl)morpholine (<b>35</b>) (2.00 g, 7.93 mmol), tetramethylammonium fluoride (813 mg, 8.73 mmol), and <i>tert</i>-butyl (3<i>S</i>)-3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>36</b>) (2.23 g, 10.3 mmol) in NMP (13.9 mL) was added diisopropylethylamine (2.71 mL, 15.9 mmol), and the yellow mixture was heated at 70 °C for 18 h. The mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine (2 × 25 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified over silica gel (20–50% EtOAc/heptanes) to give the title compound (2.54 g, 74%) as a foamy white solid. <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 6.91 (s, 1H), 4.76 (t, <i>J</i> = 5.9 Hz, 1H), 3.80–3.59 (m, 7H), 3.57–3.46 (m, 5H), 3.42–3.27 (m, 2H), 2.37–2.27 (m, 1H), 2.18–2.08 (m, 1H), 1.40 (s, 9H); LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>18</sub>H<sub>28</sub>ClFN<sub>5</sub>O<sub>4</sub> 432.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 2: Preparation of [(3<i>S</i>)-3-{[6-Chloro-5-fluoro-2-(morpholin-4-yl)pyrimidin-4-yl]amino}pyrrolidin-3-yl]methanol Hydrochloride (<b>37ci</b>)</h4><div class="NLM_p last">To a solution of <b>37c</b> (10 g, 23.3 mmol) in methanol (175 mL) was added 12 M aqueous hydrogen chloride (59 mL, 699 mmol) dropwise at 0 °C, and the reaction mixture was allowed to warm to room temperature while stirring for 18 h. The mixture was triturated with toluene followed by methanol and concentrated under reduced pressure to give the title compound (9.63 g, >99%) as a light yellow foamy solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (br s, 2H), 4.10 (br s, 6H), 3.84–3.73 (m, 3H), 3.69–3.51 (m, 7H), 3.41–3.23 (m, 3H), 2.48–2.42 (m, 1H), 2.22 (td, <i>J</i> = 13.7, 8.4 Hz, 1H). LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>13</sub>H<sub>20</sub>ClFN<sub>5</sub>O<sub>2</sub> 332.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 3: Preparation of 2,2-Difluoroethyl (3<i>S</i>)-3-{[6-Chloro-5-fluoro-2-(morpholin-4-yl)pyrimidin-4-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>39</b>)</h4><div class="NLM_p last">2,2-Difluoroethanol (0.28 mL, 4.47 mmol) was added to a solution of CDI (658 mg, 4.06 mmol) in DCM (15 mL). The resultant solution was added dropwise to a 0 °C solution of <b>37ci</b> (1.64g, 4.06 mmol) and triethylamine (1.70 mL, 12.2 mmol) in DCM (25 mL). The mixture was warmed to room temperature, and stirring was continued for 18 h. The solution was washed with water (25 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was dissolved in methanol (20 mL), and aqueous 3 M K<sub>2</sub>CO<sub>3</sub> (1.35 mL) was added at room temperature. After 20 min, the reaction mixture was partitioned between DCM and 0.05 M aqueous HCl. The organic layer was separated and concentrated to give the title compound (1.425 g, 77%) as a white foamy solid. <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 7.02–6.85 (m, 1H), 6.16 (tt, <i>J</i> = 54.90, 3.67 Hz, 1H), 4.76 (t, <i>J</i> = 5.81 Hz, 1H), 4.26 (td, <i>J</i> = 15.16, 3.42 Hz, 2H), 3.86 (d, <i>J</i> = 11.49 Hz, 1H), 3.79–3.69 (m, 2H), 3.68–3.60 (m, 5H), 3.57–3.52 (m, 4H), 3.51–3.36 (m, 2H), 2.45–2.35 (m, 1H), 2.23–2.13 (m, 1H); LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>16</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>4</sub> 440.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 4: Preparation of 2,2-Difluoroethyl (3<i>S</i>)-3-{[2′-Amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate <b>(1)</b></h4><div class="NLM_p last">To a solution of 2,2-difluoroethyl (<i>S</i>)-3-((6-chloro-5-fluoro-2-morpholinopyrimidin-4-yl)amino)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (<b>39</b>) (11.49 g, 26.124 mmol) in <i>n</i>-butanol (261 mL) were added <b>26</b> (6.93 g, 31.3 mmol) and 3 M aqueous K<sub>2</sub>CO<sub>3</sub> (34.8 mL) at room temperature, and the solution was sparged with nitrogen gas. To this solution was added Pd(dppf)Cl<sub>2</sub> (956 mg, 1.31 mmol) and bubbling of nitrogen gas was continued for 5 min. The mixture was heated at 110 °C for 1 h and then cooled to 60 °C. Water (130 mL) and ethanol (130 mL) were added, and the mixture was cooled to 0 °C. The resultant precipitate was collected by filtration, and the filter cake was washed with water (50 mL) and ethanol (50 mL). The solids were dried in a vacuum oven at 50 °C for 18 h to give a white solid (11.10 g). The solid was dissolved in AcOH (111 mL) at 60 °C and let to cool to room temperature. The solution was diluted with THF (950 mL) and Si-Thiol (23 g) was added. After stirring for 1 h, the mixture was filtered and washed with 1:9 mixture of AcOH/THF (100 mL), then concentrated under reduced pressure. The residue was triturated with water followed by methanol and concentrated to dryness. The solids were suspended in methanol (110 mL), collected by filtration, and dried in a vacuum oven at 50 °C for 18 h to give the title compound as a white solid (10.51 g, 80%). <sup>1</sup>H NMR (400 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 8.77 (s, 2H), 6.74 (s, 2H), 6.58 (s, 1H), 6.17 (tt, <i>J</i> = 54.8, 2.9 Hz, 1H), 4.77 (t, <i>J</i> = 5.7 Hz, 1H), 4.27 (td, <i>J</i> = 15.1, 3.1 Hz, 2H), 3.91 (d, <i>J</i> = 11.6 Hz, 1H), 3.81–3.72 (m, 2H), 3.70–3.64 (m, 4H), 3.64–3.60 (m, 5H), 3.55–3.38 (m, 2H), 2.47–2.38 (m, 1H), 2.20 (dt, <i>J</i> = 13.5, 7.0 Hz, 1H); <sup>13</sup>C NMR (101 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ 164.0, 158.2, 156.9, 153.6, 153.0, 142.4, 137.9, 117.8, 114.2, 66.5, 64.2, 62.8, 63.1, 53.0, 45.2, 44.8, 32.6; <sup>19</sup>F NMR (376 MHz, 80 °C, DMSO-<i>d</i><sub>6</sub>) δ −125.97, −167.33; LCMS: <i>m</i>/<i>z</i> (APCI+) for C<sub>20</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>O<sub>4</sub> 499.1 [M + H]<sup>+</sup>; HRMS: <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>8</sub>O<sub>4</sub>F<sub>3</sub>, 498.1951, found: 498.1957; OR: [α]<sub>D</sub><sup>21</sup> = +8.3° (<i>c</i> = 0.3, DMSO-<i>d</i><sub>6</sub>). IR (solid) 3330, 1718, 1579, 1477, 1441 cm<sup>–1</sup>.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Synthesis of PF-06862309 (<b>40</b>)</h3><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Preparation of 2,2-Difluoroethyl (3<i>S</i>)-3-{[2′-Amino-5-fluoro-2-(morpholin-4-yl)-4,5′-bipyrimidin-6-yl]amino}-3-[(phosphonooxy)methyl]pyrrolidine-1-carboxylate (<b>40</b>)</h4><div class="NLM_p last">To a suspension of <b>1</b> (1.60 g, 3.21 mmol) in acetonitrile (32 mL) was added pyrophosphoryl chloride (1.55 mL, 2.83 g, 11.2 mmol) at 0 °C, and the resulting mixture was stirred for 2 h at that temperature. Water (3.2 mL) was added, and the mixture was allowed to warm to room temperature over 18 h. To this mixture was added 6 N aqueous NaOH (10 mL), whereupon a white precipitate was formed. The precipitate was collected by filtration, washed with a 3:1 mixture of acetonitrile/water, and dried in a vacuum oven at 50 °C for 18 h to give a pale yellow solid. This was combined with four other parallel batches (total of 5.00 g (10.0 mmol) of compound <b>1</b>), suspended in a 6:1 mixture of THF/water (140 mL), and heated at 60 °C for 2 h. The mixture was allowed to cool at room temperature and then at 0 °C, whereupon a white precipitate was formed. The precipitate was collected by filtration washing with a 5:1 mixture of THF/water (30 mL) and dried in a vacuum over at 50 °C for 16 h. The solid was suspended in water (82 mL) and heated under reflux for 1 h, followed by addition of ethanol (4.1 mL) and a second portion of ethanol (8.2 mL) 2 h later. The mixture was stirred at 90 °C for 16 h and allowed to cool to room temperature. The resultant white precipitate was collected by filtration, washed with ethanol, and dried in a vacuum oven at 65 °C for 18 h to give the title compound (4.04 g, 78%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ 8.78 (s, 2H), 6.93 (s, 1H), 6.80 (s, 2H), 6.18 (tt, <i>J</i> = 54.8, 3.5 Hz, 1H), 4.33–4.22 (m, 4H), 3.95 (d, <i>J</i> = 11.7 Hz, 1H), 3.70–3.59 (m, 9H), 3.54–3.42 (m, 2H), 2.28–2.19 (m, 1H). (Note: one aliphatic proton obscured by DMSO-<i>d</i><sub>6</sub>.); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C) δ 164.0, 158.3, 156.8, 153.6, 152.8, 142.7, 137.8, 117.8, 114.2, 66.5, 65.9, 65.9, 63.1, 53.1, 45.3, 44.6, 32.4; HRMS: <i>m</i>/<i>z</i> [M]<sup>+</sup> calcd for C<sub>20</sub>H<sub>26</sub>N<sub>8</sub>O<sub>7</sub>F<sub>3</sub>P, 578.1614; found: 578.1604; elemental analysis: calcd for C<sub>20</sub>H<sub>26</sub>N<sub>8</sub>O<sub>7</sub>F<sub>3</sub>P·0.2H<sub>2</sub>O, C: 41.27; H: 4.57; N: 19.25; found: C: 41.03; H: 4.54; N: 18.98.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Aqueous Solubility Measurement at pH 7.4</h3><div class="NLM_p last">A 30 mM DMSO stock solution of <b>1</b> or <b>40</b> was diluted to 600 μM in PBS pH 7.4 containing 2% DMSO and incubated for 24 h at 37 °C with constant agitation (BENCHMARK Orbi-Shaker CO<sub>2</sub> shaker, set to 200 rpm). After incubation, precipitated <b>1</b> or <b>40</b> was removed by filtration through a 0.22 μm filter (Protein Crash Plates, product #60513, Analytical Sales & Service) and soluble <b>1</b> or <b>40</b> were quantitated by LC/MS/MS (Sciex API 6500). The LC/MS/MS peak intensity of soluble <b>1</b> or soluble <b>40</b> was compared to that of a matrix-matched 600 μM compound stock of <b>1</b> or <b>40</b> in DMSO, and concentration was calculated as: [soluble <b>1</b> or soluble <b>40</b> in μM] = buffer signal/DMSO signal × 600 μM.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01652" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01652?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01652</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Kinase selectivity assays; kinase selectivity data for compound <b>1</b>; biological data with standard deviation and number of tests for all of the examples in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>; cellular potency comparison between <b>1</b> and alpelisib with standard deviation and number of tests; HPLC traces for lead compounds; modeled binding mode of <b>11</b> in PI3Kβ; modeled binding mode of <b>1</b> in mTOR; synthetic procedures for compounds <b>5</b>–<b>10</b>, <b>12</b>–<b>18</b>, and <b>28</b>–<b>34</b>; enzymatic hydrolysis of <b>40</b> to <b>1</b> in vitro studies and graphs; in vivo rat PK and TK studies and graphs (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all of the compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf">jm0c01652_si_001.pdf (749.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_002.csv">jm0c01652_si_002.csv (2.54 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M">7K6M</a> for compound <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71">7K71</a> for compound <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O">7K6O</a> for compound <b>10</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a> for compound <b>11</b>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01652" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengmiao Cheng</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1761-4503" title="Orcid link">http://orcid.org/0000-0003-1761-4503</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#167e7378717b7f777938757e73787156717b777f7a3875797b"><span class="__cf_email__" data-cfemail="1d7578737a70747c72337e7578737a5d7a707c7471337e7270">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suvi T. M. Orr</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#efbc9a9986c1809d9daf88828e8683c18c8082"><span class="__cf_email__" data-cfemail="8ad9fffce3a4e5f8f8caede7ebe3e6a4e9e5e7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Bailey</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexei Brooun</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Chen</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judith G. Deal</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yali L. Deng</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin P. Edwards</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary M. Gallego</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Grodsky</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Buwen Huang</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mehran Jalaie</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Kaiser</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kania</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan E. Kephart</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Lafontaine</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martha A. Ornelas</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mason Pairish</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Planken</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8901-8992" title="Orcid link">http://orcid.org/0000-0001-8901-8992</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Sutton</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Zehnder</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chau D. Almaden</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shubha Bagrodia</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew D. Falk</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hovhannes J. Gukasyan</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caroline Ho</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaolin Kang</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel E. Kosa</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Liu</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary E. Spilker</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergei Timofeevski</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi Visswanathan</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenxiong Wang</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fanxiu Meng</span> - <span class="hlFld-Affiliation affiliation">Wuxi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shijian Ren</span> - <span class="hlFld-Affiliation affiliation">Wuxi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Shao</span> - <span class="hlFld-Affiliation affiliation">Wuxi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Xu</span> - <span class="hlFld-Affiliation affiliation">Wuxi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John C. Kath</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was prepared by H.C. and S.T.M.O. with contributions from all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">phosphatidylinositol</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hormone receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">DHPP</td><td class="NLM_def"><p class="first last">dihydropyrrolopyrimidine</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">BOC</td><td class="NLM_def"><p class="first last"><i>tert</i>-butylcarbamate</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dimethylformamide</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimide</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in die = twice a day</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+Evolution+of+Phosphatidylinositol+3-Kinases+as+Regulators+of+Growth+and+Metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0li5vlWP4XWA3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Evolution%2520of%2520Phosphatidylinositol%25203-Kinases%2520as%2520Regulators%2520of%2520Growth%2520and%2520Metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">The PI3K Pathway in Human Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.cell.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=28802037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=605-635&author=D.+A.+Frumanauthor=H.+Chiuauthor=B.+D.+Hopkinsauthor=S.+Bagrodiaauthor=L.+C.+Cantleyauthor=R.+T.+Abraham&title=The+PI3K+Pathway+in+Human+Disease&doi=10.1016%2Fj.cell.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway in Human Disease</span></div><div class="casAuthors">Fruman, David A.; Chiu, Honyin; Hopkins, Benjamin D.; Bagrodia, Shubha; Cantley, Lewis C.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-635</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer.  Many PI3K pathway-targeted therapies have been tested in oncol. trials, resulting in regulatory approval of one isoform-selective inhibitor (idelalisib) for treatment of certain blood cancers and a variety of other agents at different stages of development.  In parallel to PI3K research by cancer biologists, investigations in other fields have uncovered exciting and often unpredicted roles for PI3K catalytic and regulatory subunits in normal cell function and in disease.  Many of these functions impinge upon oncol. by influencing the efficacy and toxicity of PI3K-targeted therapies.  Here we provide a perspective on the roles of class I PI3Ks in the regulation of cellular metab. and in immune system functions, two topics closely intertwined with cancer biol.  We also discuss recent progress developing PI3K-targeted therapies for treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1NPtgicD_rVg90H21EOLACvtfcHk0li5vlWP4XWA3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL&md5=a5a5c06960587cefa95a6fb8cc647c7f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DThe%2520PI3K%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D605%26epage%3D635%26doi%3D10.1016%2Fj.cell.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">High Frequency of Mutations of the PIK3CA Gene in Human Cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">554</span>, <span class="refDoi"> DOI: 10.1126/science.1096502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptakauthor=S.+Szaboauthor=H.+Yanauthor=A.+Gazdarauthor=S.+M.+Powellauthor=G.+J.+Rigginsauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=High+Frequency+of+Mutations+of+the+PIK3CA+Gene+in+Human+Cancers&doi=10.1126%2Fscience.1096502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0ljnprPZSj6-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DHigh%2520Frequency%2520of%2520Mutations%2520of%2520the%2520PIK3CA%2520Gene%2520in%2520Human%2520Cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D554%26doi%3D10.1126%2Fscience.1096502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24748656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dienstmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+Point+of+Inhibition%3A+A+Comparative+Review+of+PI3K%2FAKT%2FmTOR+Pathway+Inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span></div><div class="casAuthors">Dienstmann, Rodrigo; Rodon, Jordi; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1031</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacol. intervention.  Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the no. of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clin. investigation.  These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K" inhibitors, which inhibit all four isoforms of class I PI3K (α, β, δ, γ); isoform-specific inhibitors of the various PI3K isoforms; allosteric and catalytic inhibitors of AKT; and ATP-competitive inhibitors of mTOR only (and thus mTORC1 and mTORC2).  With so many agents in development, clinicians are currently faced with a wide array of clin. trials investigating a multitude of inhibitors with different mechanisms of action, being used both as single agents and in combination with other therapies.  Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity.  Mol Cancer Ther; 13(5); 1021-31. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3McPbkS5dm7Vg90H21EOLACvtfcHk0ljnprPZSj6-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D&md5=7b5ef12e83be522233ad403ce3040719</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520Point%2520of%2520Inhibition%253A%2520A%2520Comparative%2520Review%2520of%2520PI3K%252FAKT%252FmTOR%2520Pathway%2520Inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+Clinical+Candidates+and+Recent+Inhibitor+Design+Strategies%3A+A+Medicinal+Chemistry+Perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0liSSkc8uhGObw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520Clinical%2520Candidates%2520and%2520Recent%2520Inhibitor%2520Design%2520Strategies%253A%2520A%2520Medicinal%2520Chemistry%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Tomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trandafir, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span> <span> </span><span class="NLM_article-title">Phase I Dose-Escalation and -Expansion Study of Buparlisib (BKM120), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">670</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0082-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1007%2Fs10637-014-0082-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24652201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=670-681&author=J.+Rodonauthor=I.+Branaauthor=L.+L.+Siuauthor=M.+J.+De+Jongeauthor=N.+Homjiauthor=D.+Millsauthor=E.+Di+Tomasoauthor=C.+Sarrauthor=L.+Trandafirauthor=C.+Massacesiauthor=F.+Eskensauthor=J.+C.+Bendell&title=Phase+I+Dose-Escalation+and+-Expansion+Study+of+Buparlisib+%28BKM120%29%2C+an+Oral+Pan-Class+I+PI3K+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors.&doi=10.1007%2Fs10637-014-0082-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Rodon, Jordi; Brana, Irene; Siu, Lillian L.; De Jonge, Maja J.; Homji, Natasha; Mills, David; Di Tomaso, Emmanuelle; Sarr, Celine; Trandafir, Lucia; Massacesi, Cristian; Eskens, Ferry; Bendell, Johanna C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">670-681</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose The pan-Class I PI3K inhibitor buparlisib (BKM120) has shown activity in a range of preclin. cancer models.  This first-in-man study was initiated to identify the max. tolerated dose (MTD) of buparlisib (100 mg/day) and to assess safety and preliminary efficacy.  Methods Patients with advanced solid tumors (N = 83) enrolled in a Phase I dose-escalation and -expansion study of single-agent buparlisib.  Patients in the dose-expansion arm (n = 43) had tumor samples with PIK3CA and/or PTEN alterations.  Results The most common cancers were colorectal (n = 31) and breast cancer (n = 21).  Median no. of prior antineoplastic regimens was four (range: 1-12).  Grade 3/4 adverse events (AEs) included asthenia (12.0 %) and performance status decrease (9.6 %).  Treatment-related AEs (all grades) included decreased appetite, diarrhea, nausea (each in 33 % of patients), hyperglycemia (31 %) and rash (29 %).  One confirmed partial response (PR; triple-neg. breast cancer) and three unconfirmed PRs (parotid gland carcinoma, epithelioid hemangiothelioma, ER + breast cancer) were reported.  Tumor mol. status did not predict clin. benefit in the full study cohort, or among the colorectal or breast cancer subpopulations.  Pharmacodynamic biomarkers (18F-FDG-PET, C-peptide, pS6) demonstrated dose-dependent changes; however, tumor heterogeneity precluded a clear correlation with clin. benefit.  Conclusion Buparlisib was well tolerated up to the 100 mg/day dose and showed preliminary activity in patients with advanced cancers.  Future studies in more homogeneous patient populations will evaluate buparlisib in combination with other agents and further investigate the use of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9JLgQd5SixbVg90H21EOLACvtfcHk0liSSkc8uhGObw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vO&md5=78ad3de32e7118c465ad608a05ae6712</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0082-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0082-9%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DBrana%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DHomji%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DD.%26aulast%3DDi%2BTomaso%26aufirst%3DE.%26aulast%3DSarr%26aufirst%3DC.%26aulast%3DTrandafir%26aufirst%3DL.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3DEskens%26aufirst%3DF.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520I%2520Dose-Escalation%2520and%2520-Expansion%2520Study%2520of%2520Buparlisib%2520%2528BKM120%2529%252C%2520an%2520Oral%2520Pan-Class%2520I%2520PI3K%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors.%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D670%26epage%3D681%26doi%3D10.1007%2Fs10637-014-0082-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span> <span> </span><span class="NLM_article-title">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1078-0432.CCR-13-1777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24166903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=233-245&author=G.+I.+Shapiroauthor=J.+Rodonauthor=C.+Bedellauthor=E.+L.+Kwakauthor=J.+Baselgaauthor=I.+Branaauthor=S.+S.+Pandyaauthor=C.+Scheffoldauthor=A.+D.+Lairdauthor=L.+T.+Nguyenauthor=Y.+Xuauthor=C.+Egileauthor=G.+Edelman&title=Phase+I+Safety%2C+Pharmacokinetic%2C+and+Pharmacodynamic+Study+of+SAR245408+%28XL147%29%2C+an+Oral+Pan-Class+I+PI3K+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-1777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shapiro, Geoffrey I.; Rodon, Jordi; Bedell, Cynthia; Kwak, Eunice L.; Baselga, Jose; Brana, Irene; Pandya, Shuchi S.; Scheffold, Christian; Laird, A. Douglas; Nguyen, Linh T.; Xu, Yi; Egile, Coumaran; Edelman, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: SAR245408 is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor.  This phase I study detd. the max. tolerated dose (MTD) of two dosing schedules [first 21 days of a 28-day period (21/7) and continuous once-daily dosing (CDD)], pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy.  Exptl. Design: Patients with refractory advanced solid malignancies were treated with SAR245408 using a 3 + 3 design.  Pharmacokinetic parameters were detd. after single and repeated doses.  Pharmacodynamic effects were evaluated in plasma, hair sheath cells, and skin and tumor biopsies.  Results: Sixty-nine patients were enrolled.  The MTD of both schedules was 600 mg; dose-limiting toxicities were maculopapular rash and hypersensitivity reaction.  The most frequent drug-related adverse events included dermatol. toxicities, diarrhea, nausea, and decreased appetite.  Plasma pharmacokinetics showed a median time to max. concn. of 8 to 22 h, mean terminal elimination half-life of 70 to 88 h, and 5- to 13-fold accumulation after daily dosing (first cycle).  Steady-state concn. was reached between days 15 and 21, and exposure was dose-proportional with doses up to 400 mg.  SAR245408 inhibited the PI3K pathway (∼40%-80% redn. in phosphorylation of AKT, PRAS40, 4EBP1, and S6 in tumor and surrogate tissues) and, unexpectedly, also inhibited the MEK/ERK pathway.  A partial response was seen in one patient with advanced non-small cell lung cancer.  Eight patients were progression-free at 6 mo.  Pharmacodynamic and clin. activity were obsd. irresp. of tumor PI3K pathway mol. alterations.  Conclusions: SAR245408 was tolerable at doses assocd. with PI3K pathway inhibition.  The recommended phase II dose of the capsule formulation is 600 mg administered orally with CDD.  Clin Cancer Res; 20(1); 233-45. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBJvsX9x4E-7Vg90H21EOLACvtfcHk0lhXUVoBTFCi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKksQ%253D%253D&md5=1f692dba8f960c733722f1956ebf2f50</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1777%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DBedell%26aufirst%3DC.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBrana%26aufirst%3DI.%26aulast%3DPandya%26aufirst%3DS.%2BS.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DEgile%26aufirst%3DC.%26aulast%3DEdelman%26aufirst%3DG.%26atitle%3DPhase%2520I%2520Safety%252C%2520Pharmacokinetic%252C%2520and%2520Pharmacodynamic%2520Study%2520of%2520SAR245408%2520%2528XL147%2529%252C%2520an%2520Oral%2520Pan-Class%2520I%2520PI3K%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D233%26epage%3D245%26doi%3D10.1158%2F1078-0432.CCR-13-1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrickson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+Phase+I+Study+of+Pictilisib+%28GDC-0941%29%2C+a+Potent+Pan-Class+I+Phosphatidylinositol-3-Kinase+%28PI3K%29+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 h·μmol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels ≥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lhXUVoBTFCi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520Phase%2520I%2520Study%2520of%2520Pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520Potent%2520Pan-Class%2520I%2520Phosphatidylinositol-3-Kinase%2520%2528PI3K%2529%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozeboom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozeboom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span> <span> </span><span class="NLM_article-title">ER+ Metastatic Breast Cancer: Past, Present, and a Prescription for an Apoptosis-targeted Future</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2821</span>– <span class="NLM_lpage">2831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=31911865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtValt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=2821-2831&author=B.+Rozeboomauthor=N.+Deyauthor=P.+Deauthor=B.+Rozeboomauthor=N.+Deyauthor=P.+Deauthor=P.+De&title=ER%2B+Metastatic+Breast+Cancer%3A+Past%2C+Present%2C+and+a+Prescription+for+an+Apoptosis-targeted+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future</span></div><div class="casAuthors">Rozeboom, Brett; Dey, Nandini; De, Pradip</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2821-2831</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">The importance and role of the estrogen receptor (ER) pathway have been well-recognized in both breast cancer development and progression.  The treatment of choice in women with estrogen receptor-pos. metastatic breast cancer (ER+ mBC) is classically divided into a variety of endocrine therapies, with three of the most common being: selective estrogen receptor modulators (SERM), aromatase inhibitors (AI), and selective estrogen receptor degraders (SERD).  However, resistance develops in 30-50% of patients treated with these endocrine therapies due to a sophisticated and at times redundant interference at the mol. level between the ER, growth factors, and downstream cell-signaling pathways.  Tumor response is heightened with adjunctive therapy that includes an mTORC1 inhibitor (everolimus), CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib), and an a isoform-specifi PI3K inhibitor (alpelisib).  Each of these inhibitors elicits potent anti-proliferative benefis; however, they fail to induce tumor cell death.  Consequently, disease progression almost invariably occurs.  Evasion of apoptosis is a hallmark of cancer.  The p53 and BCL2 represent two important nodes of the apoptosis signaling pathway.  Venetoclax, a potent and selective BCL2 inhibitor, synergizes with hormonal therapy in ER+ breast cancer models and is active in clin. trials.  Similarly, an MDM2 inhibitor, AMG-232, which induces p53 is active in early clin. trials of both liq. and advanced solid tumor patients.  In our ER+ BC cohort (Avera Cancer Institute, Sioux Falls, SD), we obsd. more than 70% of wild type TP53 and over 10% amplifiation of MDM2 and MDM4 as comparable with the TCGA data set.  We summarized current treatment options, the mol. mechanisms that predispose to endocrine resistance, and a future pro-apoptotic treatment strategy for ER+ mBC patients.  Our review presents crit. analyses of the therapeutic options for the clin. management of ER+ Metastatic Breast Cancer in the light of a hypothesis targeting the induction of apoptosis in p53 wild type tumors.  We reviewed not only the FDA approved current treatment approaches but also presented a discourse addressing the possibilities for novel combination strategy that can induce tumor cell apoptosis, a crit. cellular mechanism delaying/denying tumor progression.  Our review is unique as it presents patient data in support of our hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6rjMDMCoKLVg90H21EOLACvtfcHk0lgtwWUXwkUjxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtValt7rI&md5=d71fe9f29e40e2e4a4895921f4df1ae7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRozeboom%26aufirst%3DB.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DRozeboom%26aufirst%3DB.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DDe%26aufirst%3DP.%26atitle%3DER%252B%2520Metastatic%2520Breast%2520Cancer%253A%2520Past%252C%2520Present%252C%2520and%2520a%2520Prescription%2520for%2520an%2520Apoptosis-targeted%2520Future%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2019%26volume%3D9%26spage%3D2821%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase α-Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results from the First-in-human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+%CE%B1-Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+PIK3CA-Altered+Solid+Tumors%3A+Results+from+the+First-in-human+Study&doi=10.1200%2FJCO.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0lgtwWUXwkUjxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%25CE%25B1-Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520PIK3CA-Altered%2520Solid%2520Tumors%253A%2520Results%2520from%2520the%2520First-in-human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2FJCO.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatenay-Rivauday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=P.+A.+Deauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.-M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+Novel+and+Specific+PI3K%CE%B1+Inhibitor+NVP-BYL719+and+Development+of+the+Patient+Stratification+Strategy+for+Clinical+Trials&doi=10.1158%2F1535-7163.MCT-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0ljuAxlMtoqIkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DP.%2BA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520and%2520Specific%2520PI3K%25CE%25B1%2520Inhibitor%2520NVP-BYL719%2520and%2520Development%2520of%2520the%2520Patient%2520Stratification%2520Strategy%2520for%2520Clinical%2520Trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.MCT-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M.-G.</span>; <span class="NLM_string-name">Chan, C.</span>; <span class="NLM_string-name">Clausen, S.</span>; <span class="NLM_string-name">Edgar, K.</span>; <span class="NLM_string-name">Eigenbrot, C.</span>; <span class="NLM_string-name">Eliott, R.</span>; <span class="NLM_string-name">Endres, N.</span>; <span class="NLM_string-name">Friedman, L.</span>; <span class="NLM_string-name">Gerland, K.</span>; <span class="NLM_string-name">Gu, X.-H.</span>; <span class="NLM_string-name">Hamilton, P.</span>; <span class="NLM_string-name">Han, C.</span>; <span class="NLM_string-name">Hanan, E.</span>; <span class="NLM_string-name">Hong, R.</span>; <span class="NLM_string-name">Jackson, P.</span>; <span class="NLM_string-name">Kelly, S.</span>; <span class="NLM_string-name">Knight, J.</span>; <span class="NLM_string-name">Lee, M.-L.</span>; <span class="NLM_string-name">Lu, A.</span>; <span class="NLM_string-name">MacLeod, C.</span>; <span class="NLM_string-name">McKenzie, A.</span>; <span class="NLM_string-name">Nannini, M.</span>; <span class="NLM_string-name">Narukulla, R.</span>; <span class="NLM_string-name">Nguyen, A.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Purkey, H.</span>; <span class="NLM_string-name">Salphati, L.</span>; <span class="NLM_string-name">Sampath, D.</span>; <span class="NLM_string-name">Schmidt, S.</span>; <span class="NLM_string-name">Schutt, L.</span>; <span class="NLM_string-name">Heald, R.</span>; <span class="NLM_string-name">Song, K.</span>; <span class="NLM_string-name">Ultsch, M.</span>; <span class="NLM_string-name">Xin, J.</span>; <span class="NLM_string-name">Yeap, K.</span>; <span class="NLM_string-name">Young, A.</span>; <span class="NLM_string-name">Zhong, Z.</span>; <span class="NLM_string-name">Staben, S.</span></span> <i>Discovery of GDC-0077: A Highly Selective Inhibitor of PI3K-Alpha That Induces Degradation of Mutant-p110 Alpha Protein</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2017</span>; p  <span class="NLM_fpage">MEDI-22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=MEDI-22&author=M.-G.+Braun&author=C.+Chan&author=S.+Clausen&author=K.+Edgar&author=C.+Eigenbrot&author=R.+Eliott&author=N.+Endres&author=L.+Friedman&author=K.+Gerland&author=X.-H.+Gu&author=P.+Hamilton&author=C.+Han&author=E.+Hanan&author=R.+Hong&author=P.+Jackson&author=S.+Kelly&author=J.+Knight&author=M.-L.+Lee&author=A.+Lu&author=C.+MacLeod&author=A.+McKenzie&author=M.+Nannini&author=R.+Narukulla&author=A.+Nguyen&author=J.+Pang&author=H.+Purkey&author=L.+Salphati&author=D.+Sampath&author=S.+Schmidt&author=L.+Schutt&author=R.+Heald&author=K.+Song&author=M.+Ultsch&author=J.+Xin&author=K.+Yeap&author=A.+Young&author=Z.+Zhong&author=S.+Staben&title=Discovery+of+GDC-0077%3A+A+Highly+Selective+Inhibitor+of+PI3K-Alpha+That+Induces+Degradation+of+Mutant-p110+Alpha+Protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DM.-G.%26btitle%3DDiscovery%2520of%2520GDC-0077%253A%2520A%2520Highly%2520Selective%2520Inhibitor%2520of%2520PI3K-Alpha%2520That%2520Induces%2520Degradation%2520of%2520Mutant-p110%2520Alpha%2520Protein%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2017%26spage%3DMEDI-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Monomeric Targeted Protein Degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11330</span>– <span class="NLM_lpage">11361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotl2qsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11330-11361&author=E.+J.+Hananauthor=J.+Liangauthor=X.+Wangauthor=R.+Blakeauthor=N.+Blaquiereauthor=S.+T.+Staben&title=Monomeric+Targeted+Protein+Degraders&doi=10.1021%2Facs.jmedchem.0c00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Monomeric Targeted Protein Degraders</span></div><div class="casAuthors">Hanan, Emily J.; Liang, Jun; Wang, Xiaojing; Blake, Robert A.; Blaquiere, Nicole; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11330-11361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chem.  Inducing degrdn. of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacol.  While engineered heterodimeric mols. have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degrdn. obsd. for smaller, monomeric mols.  Methods and tools for evaluating protein degrdn. as well as a discussion of phys. properties of monomeric vs engineered heterodimeric degraders are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqys0SNWcaCTLVg90H21EOLACvtfcHk0ljuAxlMtoqIkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotl2qsbY%253D&md5=bd4c3240f66ef2f7611fdffde6ec5c3a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DMonomeric%2520Targeted%2520Protein%2520Degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11330%26epage%3D11361%26doi%3D10.1021%2Facs.jmedchem.0c00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 Through Structure Based Drug Design</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1039/c0md00072h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1039%2Fc0md00072h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVansL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=139-144&author=H.+Chengauthor=S.+Bagrodiaauthor=S.+Baileyauthor=M.+Edwardsauthor=J.+Hoffmanauthor=Q.-Y.+Huauthor=R.+Kaniaauthor=D.+R.+Knightonauthor=M.+A.+Marxauthor=S.+Ninkovicauthor=S.+Sunauthor=E.+Zhang&title=Discovery+of+the+Highly+Potent+PI3K%2FmTOR+Dual+Inhibitor+PF-04691502+Through+Structure+Based+Drug+Design&doi=10.1039%2Fc0md00072h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design</span></div><div class="casAuthors">Cheng, Hengmiao; Bagrodia, Shubha; Bailey, Simon; Edwards, Martin; Hoffman, Jacqui; Hu, Qi-Yue; Kania, Robert; Knighton, Daniel R.; Marx, Matthew A.; Ninkovic, Sacha; Sun, Shaoxian; Zhang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-144</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays crucial roles in cell growth, proliferation and survival.  Genomic aberrations in the PI3K pathway, such as mutational activation of PI3Kα or loss of function of tumor suppressor PTEN, have been closely linked to the development and progression of a wide range of cancers.  Hence, inhibition of the key targets in the pathway, e.g.  PI3K, AKT, mTOR, offers great potential for the treatment of cancer.  Lead optimization through integration of structure based drug design (SBDD) and phys. properties-based optimization (PPBO) led to the discovery of 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502, 1) that demonstrated potent in vitro inhibitory activity against both PI3K and mTOR, excellent kinase selectivity, good ADMET, and robust in vivo efficacy in a mouse xenograft tumor growth model.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQLpVG9peoLVg90H21EOLACvtfcHk0ljuAxlMtoqIkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVansL7P&md5=2fe2649dd9cd51fcf09ae13fa529fcb2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1039%2Fc0md00072h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00072h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FmTOR%2520Dual%2520Inhibitor%2520PF-04691502%2520Through%2520Structure%2520Based%2520Drug%2520Design%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D139%26epage%3D144%26doi%3D10.1039%2Fc0md00072h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-based Drug Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/ml300309h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300309h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=91-97&author=H.+Chengauthor=C.+Liauthor=S.+Baileyauthor=S.+M.+Baxiauthor=L.+Gouletauthor=L.+Guoauthor=J.+Hoffmanauthor=Y.+Jiangauthor=T.+O.+Johnsonauthor=T.+W.+Johnsonauthor=D.+R.+Knightonauthor=J.+Liauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=M.+A.+Marxauthor=M.+Wallsauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=J.+Zhuauthor=M.+Zientek&title=Discovery+of+the+Highly+Potent+PI3K%2FmTOR+Dual+Inhibitor+PF-04979064+through+Structure-based+Drug+Design&doi=10.1021%2Fml300309h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span></div><div class="casAuthors">Cheng, Hengmiao; Li, Chunze; Bailey, Simon; Baxi, Sangita M.; Goulet, Lance; Guo, Lisa; Hoffman, Jacqui; Jiang, Ying; Johnson, Theodore Otto; Johnson, Ted W.; Knighton, Daniel R.; Li, John; Liu, Kevin K.-C.; Liu, Zhengyu; Marx, Matthew A.; Walls, Marlena; Wells, Peter A.; Yin, Min-Jean; Zhu, Jinjiang; Zientek, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncol.  To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clin. trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series.  Integration of structure-based drug design and phys. properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064 (I).  This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a no. of ADMET issues including high metabolic clearance mediated by both P 450 and aldehyde oxidase (AO), poor permeability, and poor soly.  An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivs. that were AO substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsQSJqL-ssP7Vg90H21EOLACvtfcHk0lgazi3F-OiPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I&md5=0059c9c220419aad748b4fcde92c28bb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml300309h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300309h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZientek%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FmTOR%2520Dual%2520Inhibitor%2520PF-04979064%2520through%2520Structure-based%2520Drug%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D91%26epage%3D97%26doi%3D10.1021%2Fml300309h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paderes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span> <span> </span><span class="NLM_article-title">Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1021/ml200126j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200126j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=809-813&author=K.+K.+C.+Liuauthor=J.+J.+Zhuauthor=G.+L.+Smithauthor=M.-J.+Yinauthor=S.+Baileyauthor=J.+H.+Chenauthor=Q.+Huauthor=Q.+Huangauthor=C.+Liauthor=Q.+J.+Liauthor=M.+A.+Marxauthor=G.+Paderesauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=M.+Wallsauthor=P.+A.+Wellsauthor=A.+Zou&title=Highly+Selective+and+Potent+Thiophenes+as+PI3K+Inhibitors+with+Oral+Antitumor+Activity&doi=10.1021%2Fml200126j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity</span></div><div class="casAuthors">Liu, Kevin K.-C.; Zhu, Jin Jiang; Smith, Graham L.; Yin, Min-Jean; Bailey, Simon; Chen, Jeffrey H.; Hu, Qiyue; Huang, Qinhua; Li, Chunze; Li, Qing J.; Marx, Matthew A.; Paderes, Genevieve; Richardson, Paul F.; Sach, Neal W.; Walls, Marlena; Wells, Peter A.; Baxi, Sangita; Zou, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly selective PI3K inhibitors with subnanomolar PI3Kα potency and greater than 7000-fold selectivity against mTOR kinase were discovered through structure-based drug design (SBDD).  These tetra-substituted thiophenes were also demonstrated to have good in vitro cellular potency and good in vivo oral antitumor activity in a mouse PI3K driven NCI-H1975 xenograft tumor model.  Compds. with the desired human PK predictions and good in vitro ADMET properties were also identified.  In this communication, we describe the rationale behind the installation of a crit. triazole moiety to maintain the intricate H-bonding network within the PI3K receptor leading to both better potency and selectivity.  Furthermore, optimization of the C-4 Ph group was exploited to maximize the compds. mTOR selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVf_CRUykT9bVg90H21EOLACvtfcHk0lgazi3F-OiPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7fL&md5=9cb3f49dfc251f6347de5e17ca8b3bba</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml200126j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200126j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%2BJ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DPaderes%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DZou%26aufirst%3DA.%26atitle%3DHighly%2520Selective%2520and%2520Potent%2520Thiophenes%2520as%2520PI3K%2520Inhibitors%2520with%2520Oral%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D809%26epage%3D813%26doi%3D10.1021%2Fml200126j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur Rogers, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Kα and mTOR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5098</span>– <span class="NLM_lpage">5103</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2012.05.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=22749419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5098-5103&author=P.+T.+Leauthor=H.+Chengauthor=S.+Ninkovicauthor=M.+Pleweauthor=X.+Huangauthor=H.+Wangauthor=S.+Bagrodiaauthor=S.+Sunauthor=D.+R.+Knightonauthor=C.+M.+LaFleur+Rogersauthor=A.+Panniferauthor=S.+Greasleyauthor=D.+Dalvieauthor=E.+Zhang&title=Design+and+Synthesis+of+a+Novel+Pyrrolidinyl+Pyrido+Pyrimidinone+Derivative+as+a+Potent+Inhibitor+of+PI3K%CE%B1+and+mTOR&doi=10.1016%2Fj.bmcl.2012.05.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR</span></div><div class="casAuthors">Le, Phuong T.; Cheng, Hengmiao; Ninkovic, Sacha; Plewe, Michael; Huang, Xiaojun; Wang, Hai; Bagrodia, Shubha; Sun, Shaoxian; Knighton, Daniel R.; LaFleur Rogers, Caroline M.; Pannifer, Andrew; Greasley, Samantha; Dalvie, Deepak; Zhang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5098-5103</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lead optimization efforts that employed structure base drug design and physicochem. property based optimization leading to the discovery of a novel series of 4-methylpyrido pyrimidinone (MPP) are discussed.  Synthesis and profile of I, a PI3Kα/mTOR dual inhibitor, is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCna8LjcDc7rVg90H21EOLACvtfcHk0lgazi3F-OiPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1KnsL8%253D&md5=14685f94189ea6f4571f061f6e2c4d1b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DPlewe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLaFleur%2BRogers%26aufirst%3DC.%2BM.%26aulast%3DPannifer%26aufirst%3DA.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Pyrrolidinyl%2520Pyrido%2520Pyrimidinone%2520Derivative%2520as%2520a%2520Potent%2520Inhibitor%2520of%2520PI3K%25CE%25B1%2520and%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5098%26epage%3D5103%26doi%3D10.1016%2Fj.bmcl.2012.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahavendran, S. V.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design, SAR Analysis and Antitumor Activity of PI3K/mTOR Dual Inhibitors from 4-Methylpyridopyrimidinone Series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2013.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=23506825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlGntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2787-2792&author=H.+Chengauthor=J.+E.+Hoffmanauthor=P.+T.+Leauthor=M.+Pairishauthor=R.+Kaniaauthor=W.+Farrellauthor=S.+Bagrodiaauthor=J.+Yuanauthor=S.+Sunauthor=E.+Zhangauthor=C.+Xiangauthor=D.+Dalvieauthor=S.+V.+Rahavendran&title=Structure-based+Design%2C+SAR+Analysis+and+Antitumor+Activity+of+PI3K%2FmTOR+Dual+Inhibitors+from+4-Methylpyridopyrimidinone+Series&doi=10.1016%2Fj.bmcl.2013.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series</span></div><div class="casAuthors">Cheng, Hengmiao; Hoffman, Jacqui E.; Le, Phuong T.; Pairish, Mason; Kania, Robert; Farrell, William; Bagrodia, Shubha; Yuan, Jing; Sun, Shaoxian; Zhang, Eric; Xiang, Cathy; Dalvie, Deepak; Rahavendran, Sadayappan V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2787-2792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3K, AKT and mTOR, key kinases from a frequently dysregulated PI3K signaling pathway, have been extensively pursued to treat a variety of cancers in oncol.  Clin. trials of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR, from 4-methylpyridopyrimidinone series, led to the discovery of a metabolite with a terminal carboxylic acid, PF-06465603.  This paper discusses structure-based drug design, SAR and antitumor activity of the MPP derivs. with a terminal alc., a carboxylic acid or a carboxyl amide e. g., I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXKbI5bhsyd7Vg90H21EOLACvtfcHk0li5w5sNF4fFzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlGntL4%253D&md5=f0a588adb95f94f9c952ced10f91f2b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DW.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DRahavendran%26aufirst%3DS.%2BV.%26atitle%3DStructure-based%2520Design%252C%2520SAR%2520Analysis%2520and%2520Antitumor%2520Activity%2520of%2520PI3K%252FmTOR%2520Dual%2520Inhibitors%2520from%25204-Methylpyridopyrimidinone%2520Series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2787%26epage%3D2792%26doi%3D10.1016%2Fj.bmcl.2013.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and Biological Activity of a Novel Class I PI3K Inhibitor, CH5132799</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2011.01.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=21316229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslKjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1767-1772&author=J.+Ohwadaauthor=H.+Ebiikeauthor=H.+Kawadaauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=T.+Miyazakiauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=O.+Kondohauthor=S.+Kuramotoauthor=K.+Ogawaauthor=Y.+Aokiauthor=N.+Shimma&title=Discovery+and+Biological+Activity+of+a+Novel+Class+I+PI3K+Inhibitor%2C+CH5132799&doi=10.1016%2Fj.bmcl.2011.01.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799</span></div><div class="casAuthors">Ohwada, Jun; Ebiike, Hirosato; Kawada, Hatsuo; Tsukazaki, Masao; Nakamura, Mitsuaki; Miyazaki, Takuya; Morikami, Kenji; Yoshinari, Kiyoshi; Yoshida, Miyuki; Kondoh, Osamu; Kuramoto, Shino; Ogawa, Kotaro; Aoki, Yuko; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1767-1772</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer.  Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton.  Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety.  CH5132799 (I), a novel class I PI3K inhibitor, exhibited a strong inhibitory activity esp. against PI3Kα (IC50 = 0.014 μM).  In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity.  CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4CnvKaeZRFrVg90H21EOLACvtfcHk0li5w5sNF4fFzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslKjsLw%253D&md5=502b8e8430388cc5a0ef548859f7294a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520Biological%2520Activity%2520of%2520a%2520Novel%2520Class%2520I%2520PI3K%2520Inhibitor%252C%2520CH5132799%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1767%26epage%3D1772%26doi%3D10.1016%2Fj.bmcl.2011.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Class+I+PI3+Kinase+Inhibitor+for+Treating+Cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lhNm5twEnYN2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Class%2520I%2520PI3%2520Kinase%2520Inhibitor%2520for%2520Treating%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kestell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, S. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7105</span>– <span class="NLM_lpage">7126</span>, <span class="refDoi"> DOI: 10.1021/jm200688y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200688y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7105-7126&author=G.+W.+Rewcastleauthor=S.+A.+Gamageauthor=J.+U.+Flanaganauthor=R.+Frederickauthor=W.+A.+Dennyauthor=B.+C.+Baguleyauthor=P.+Kestellauthor=R.+Singhauthor=J.+D.+Kendallauthor=E.+S.+Marshallauthor=C.+L.+Lillauthor=W.-J.+Leeauthor=S.+Kolekarauthor=C.+M.+Buchananauthor=S.+M.+F.+Jamiesonauthor=P.+R.+Shepherd&title=Synthesis+and+Biological+Evaluation+of+Novel+Analogues+of+the+Pan+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitor+2-%28Difluoromethyl%29-1-%5B4%2C6-di%284-morpholinyl%29-1%2C3%2C5-triazin-2-yl%5D-1H-benzimidazole+%28ZSTK474%29&doi=10.1021%2Fjm200688y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-Kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span></div><div class="casAuthors">Rewcastle, Gordon W.; Gamage, Swarna A.; Flanagan, Jack U.; Frederick, Raphael; Denny, William A.; Baguley, Bruce C.; Kestell, Philip; Singh, Ripudaman; Kendall, Jackie D.; Marshall, Elaine S.; Lill, Claire L.; Lee, Woo-Jeong; Kolekar, Sharada; Buchanan, Christina M.; Jamieson, Stephen M. F.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7105-7126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) I identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivs.  The 6-amino-4-methoxy analog II displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy III analog against all three class Ia PI 3-kinase enzymes (p110α, p110β, and p110δ) and also displayed significant potency against two mutant forms of the p110α isoform (H1047R and E545K).  This compd. was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1-/- mice, and at a dose of 50 mg/kg given by i.p. injection at a qd × 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirsalawdjHrVg90H21EOLACvtfcHk0lhQQJhUlbYGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ&md5=250fb3eeb02505e2a5b24fd511ec94f3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm200688y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200688y%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%2BF.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Analogues%2520of%2520the%2520Pan%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%25202-%2528Difluoromethyl%2529-1-%255B4%252C6-di%25284-morpholinyl%2529-1%252C3%252C5-triazin-2-yl%255D-1H-benzimidazole%2520%2528ZSTK474%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7105%26epage%3D7126%26doi%3D10.1021%2Fjm200688y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrit, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weismann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-Kinase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/ml1001932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yhsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=34-38&author=M.+T.+Burgerauthor=M.+Knappauthor=A.+Wagmanauthor=Z.-J.+Niauthor=T.+Hendricksonauthor=G.+Atallahauthor=Y.+Zhangauthor=K.+Frazierauthor=J.+Verhagenauthor=K.+Pfisterauthor=S.+Ngauthor=A.+Smithauthor=S.+Bartulisauthor=H.+Merritauthor=M.+Weismannauthor=X.+Xinauthor=J.+Haznedarauthor=C.+F.+Volivaauthor=E.+Iwanowiczauthor=S.+Pecchi&title=Synthesis+and+in+Vitro+and+in+Vivo+Evaluation+of+Phosphoinositide-3-Kinase+Inhibitors&doi=10.1021%2Fml1001932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors</span></div><div class="casAuthors">Burger, Matthew T.; Knapp, Mark; Wagman, Allan; Ni, Zhi-Jie; Hendrickson, Thomas; Atallah, Gordana; Zhang, Yanchen; Frazier, Kelly; Verhagen, Joelle; Pfister, Keith; Ng, Simon; Smith, Aaron; Bartulis, Sarah; Merrit, Hanne; Weismann, Marion; Xin, Xiaohua; Haznedar, Joshua; Voliva, Charles F.; Iwanowicz, Ed; Pecchi, Sabina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3K) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  A series of 2-morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks.  Herein, we describe the structure-guided optimization of these pyrimidines with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties.  A series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines, which potently inhibit PI3K, were discovered.  Within this series a compd. (I) was identified with suitable pharmacokinetic (PK) properties, which allowed for the establishment of a PI3K PK/pharmacodynamic-efficacy relationship as detd. by in vivo inhibition of AKTSer473 phosphorylation and tumor growth inhibition in a mouse A2780 tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFT_jbWymff7Vg90H21EOLACvtfcHk0lhQQJhUlbYGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yhsLzM&md5=887fc3a37de2a495a9edceaa00a251f7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fml1001932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001932%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DMerrit%26aufirst%3DH.%26aulast%3DWeismann%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DPecchi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Phosphoinositide-3-Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D34%26epage%3D38%26doi%3D10.1021%2Fml1001932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0lhQQJhUlbYGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7815</span>– <span class="NLM_lpage">7833</span>, <span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Q.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+Design+of+Phosphoinositide+3-Kinase+%CE%B1+Inhibitors+That+Exhibit+Selectivity+over+the+Phosphoinositide+3-Kinase+%CE%B2+Isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0lgzwsNfYoYhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520Design%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B1%2520Inhibitors%2520That%2520Exhibit%2520Selectivity%2520over%2520the%2520Phosphoinositide%25203-Kinase%2520%25CE%25B2%2520Isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2-4-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5Dimidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0lgzwsNfYoYhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2-4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic Efficiency as an Important Metric in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+Efficiency+as+an+Important+Metric+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0ljcXc08Af0Nlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520Efficiency%2520as%2520an%2520Important%2520Metric%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Deal, J. G.</span>; <span class="NLM_string-name">Gallego, G. M.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Orr, S. T. M.</span>; <span class="NLM_string-name">Shen, H.</span>; <span class="NLM_string-name">Zehnder, L. R.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrrolopyrimidine Derivatives as PI3Kα Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2015155624A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Chen&author=H.+Cheng&author=J.+G.+Deal&author=G.+M.+Gallego&author=M.+Jalaie&author=J.+C.+Kath&author=S.+T.+M.+Orr&author=H.+Shen&author=L.+R.+Zehnder&title=Dihydropyrrolopyrimidine+Derivatives+as+PI3K%CE%B1+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26atitle%3DDihydropyrrolopyrimidine%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlaeger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuensch, B.</span></span> <span> </span><span class="NLM_article-title">Novel, One-pot Procedure for the Synthesis of 2-Arylethanol Derivatives</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1067021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1055%2Fs-2008-1067021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=1793-1797&author=T.+Schlaegerauthor=C.+Oberdorfauthor=B.+Tewesauthor=B.+Wuensch&title=Novel%2C+One-pot+Procedure+for+the+Synthesis+of+2-Arylethanol+Derivatives&doi=10.1055%2Fs-2008-1067021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1067021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1067021%26sid%3Dliteratum%253Aachs%26aulast%3DSchlaeger%26aufirst%3DT.%26aulast%3DOberdorf%26aufirst%3DC.%26aulast%3DTewes%26aufirst%3DB.%26aulast%3DWuensch%26aufirst%3DB.%26atitle%3DNovel%252C%2520One-pot%2520Procedure%2520for%2520the%2520Synthesis%2520of%25202-Arylethanol%2520Derivatives%26jtitle%3DSynthesis%26date%3D2008%26volume%3D11%26spage%3D1793%26epage%3D1797%26doi%3D10.1055%2Fs-2008-1067021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Gallego, G. M.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Orr, S. T. M.</span>; <span class="NLM_string-name">Pairish, M. A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine Derivatives as PI3Kα Inhibitors and their Preparation</span>. <span class="NLM_patent">WO2017009751A1</span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Chen&author=H.+Cheng&author=G.+M.+Gallego&author=M.+Jalaie&author=J.+C.+Kath&author=S.+T.+M.+Orr&author=M.+A.+Pairish&title=Pyrimidine+Derivatives+as+PI3K%CE%B1+Inhibitors+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26atitle%3DPyrimidine%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%2520and%2520their%2520Preparation%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubovic, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortsman, J.</span></span> <span> </span><span class="NLM_article-title">Alkaline Phosphatase (EC 3.1.3.1) in Serum Is Inhibited by Physiological Concentrations of Inorganic Phosphate</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">3951</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1210/jc.83.11.3951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1210%2Fjc.83.11.3951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=9814474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaK1cXntlOit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=3951-3957&author=S.+P.+Coburnauthor=J.+D.+Mahurenauthor=M.+Jainauthor=Y.+Zubovicauthor=J.+Wortsman&title=Alkaline+Phosphatase+%28EC+3.1.3.1%29+in+Serum+Is+Inhibited+by+Physiological+Concentrations+of+Inorganic+Phosphate&doi=10.1210%2Fjc.83.11.3951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate</span></div><div class="casAuthors">Coburn, Stephen P.; Mahuren, J. Dennis; Jain, Manas; Zubovic, Yvonne; Wortsman, Jacobo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3951-3957</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Natural and artificial manipulation of tissue nonspecific alk. phosphatase activity indicates that pyrophosphate, phosphoethanolamine, and pyridoxal 5'-phosphate are among the natural substrates for this enzyme.  Although inorg. phosphate has been recognized as a competitive inhibitor of this enzyme for many years, the influence of phosphate on alk. phosphatase activity in serum under physiol. conditions has not been previously reported.  Here, the authors examd. the kinetics of tissue nonspecific alk. phosphatase from bovine kidney and sera from 49 patients with a wide range of endogenous phosphate concns. using pyridoxine 5'-phosphate as a substrate at pH 7.4.  For the bovine kidney enzyme, the Km was 0.42 μM, and the Ki for phosphate was 2.4 μM.  Anal. of the kinetics using pyridoxine 5'-phosphate in undiluted serum from 10 subjects with P in the range of 0.5-2.1 mM and alk. phosphatase activity in the range of 41-165 nmol/min/mL gave ests. for the Km of 56 μM and for the Ki of 540 μM for phosphate.  This indicated that under physiol. conditions alk. phosphatase activity toward pyridoxine 5'-phosphate is reduced ∼50% by the normal phosphate concn. and that it will increase or decrease significantly in response to changes in phosphate concn. within the ranges obsd. clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_g2bgDndbj7Vg90H21EOLACvtfcHk0ljcXc08Af0Nlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlOit7o%253D&md5=97cecacda1e9f6f14e8bb57d3db191e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1210%2Fjc.83.11.3951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.83.11.3951%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DS.%2BP.%26aulast%3DMahuren%26aufirst%3DJ.%2BD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DZubovic%26aufirst%3DY.%26aulast%3DWortsman%26aufirst%3DJ.%26atitle%3DAlkaline%2520Phosphatase%2520%2528EC%25203.1.3.1%2529%2520in%2520Serum%2520Is%2520Inhibited%2520by%2520Physiological%2520Concentrations%2520of%2520Inorganic%2520Phosphate%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1998%26volume%3D83%26spage%3D3951%26epage%3D3957%26doi%3D10.1210%2Fjc.83.11.3951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span> <span> </span><span class="NLM_article-title">Engineering of an Isolated p110α Subunit of PI3Kα Permits Crystallization and Provides a Platform for Structure-based Drug Design</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1002/pro.2517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1002%2Fpro.2517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=25043846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1332-1340&author=P.+Chenauthor=Y.-L.+Dengauthor=S.+Bergqvistauthor=M.+D.+Falkauthor=W.+Liuauthor=S.+Timofeevskiauthor=A.+Brooun&title=Engineering+of+an+Isolated+p110%CE%B1+Subunit+of+PI3K%CE%B1+Permits+Crystallization+and+Provides+a+Platform+for+Structure-based+Drug+Design&doi=10.1002%2Fpro.2517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design</span></div><div class="casAuthors">Chen, Ping; Deng, Ya-Li; Bergqvist, Simon; Falk, Matthew D.; Liu, Wei; Timofeevski, Sergei; Brooun, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1332-1340</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PI3Kα remains an attractive target for the development of anticancer targeted therapy.  A no. of p110α crystal structures in complex with the nSH2-iSH2 fragment of p85 regulatory subunit have been reported, including a few small mol. co-crystal structures, but the utilization of this crystal form is limited by low diffraction resoln. and a crystal packing artifact that partially blocks the ATP binding site.  Taking advantage of recent data on the functional characterization of the lipid binding properties of p110α, we designed a set of novel constructs allowing prodn. of isolated stable p110α subunit missing the adapter-binding domain and lacking or featuring a modified C-terminal lipid binding motif.  While this protein is not catalytically competent to phosphorylate its substrate PIP2, it retains ligand binding properties as indicated by direct binding studies with a pan-PI3Kα inhibitor.  Addnl., we detd. apo and PF-04691502 bound crystal structures of the p110α (105-1048) subunit at 2.65 and 2.85 Å, resp.  Comparison of isolated p110α(105-1048) with the p110α/p85 complex reveals a high degree of structural similarity, which validates suitability of this catalytically inactive p110α for iterative SBDD.  Importantly, this crystal form of p110α readily accommodates the binding of noncovalent inhibitor by means of a fully accessible ATP site.  The strategy presented here can be also applied to structural studies of other members of PI3KIA family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3QqobJxobLVg90H21EOLACvtfcHk0lhzpMPXVxrZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3I&md5=4edd5247eb9e8729dc63d50713fd5314</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpro.2517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2517%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26atitle%3DEngineering%2520of%2520an%2520Isolated%2520p110%25CE%25B1%2520Subunit%2520of%2520PI3K%25CE%25B1%2520Permits%2520Crystallization%2520and%2520Provides%2520a%2520Platform%2520for%2520Structure-based%2520Drug%2520Design%26jtitle%3DProtein%2520Sci.%26date%3D2014%26volume%3D23%26spage%3D1332%26epage%3D1340%26doi%3D10.1002%2Fpro.2517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafidi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHarg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span> <span> </span><span class="NLM_article-title">PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2199</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-11-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=21750219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2189-2199&author=J.+Yuanauthor=P.+P.+Mehtaauthor=M.-J.+Yinauthor=S.+Sunauthor=A.+Zouauthor=J.+Chenauthor=K.+Rafidiauthor=Z.+Fengauthor=J.+Nickelauthor=J.+Engebretsenauthor=J.+Hallinauthor=A.+Blasinaauthor=E.+Zhangauthor=L.+Nguyenauthor=M.+Sunauthor=P.+K.+Vogtauthor=A.+McHargauthor=H.+Chengauthor=J.+G.+Christensenauthor=J.+L.+C.+Kanauthor=S.+Bagrodia&title=PF-04691502%2C+a+Potent+and+Selective+Oral+Inhibitor+of+PI3K+and+mTOR+Kinases+with+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-11-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity</span></div><div class="casAuthors">Yuan, Jing; Mehta, Pramod P.; Yin, Min-Jean; Sun, Shaoxian; Zou, Aihua; Chen, Jeffrey; Rafidi, Kristina; Feng, Zheng; Nickel, Jeffrey; Engebretsen, Jon; Hallin, Jill; Blasina, Alessandra; Zhang, Eric; Nguyen, Leslie; Sun, Minghao; Vogt, Peter K.; McHarg, Aileen; Cheng, Hengmiao; Christensen, James G.; Kan, Julie L. C.; Bagrodia, Shubha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2189-2199</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently in human cancer and contributes to resistance to antitumor therapies.  Inhibition of key signaling proteins in the pathway therefore represents a valuable targeting strategy for diverse cancers.  PF-04691502 is an ATP-competitive PI3K/mTOR dual inhibitor, which potently inhibited recombinant class I PI3K and mTOR in biochem. assays and suppressed transformation of avian fibroblasts mediated by wild-type PI3K γ, δ, or mutant PI3Kα.  In PIK3CA-mutant and PTEN-deleted cancer cell lines, PF-04691502 reduced phosphorylation of AKT T308 and AKT S473 (IC50 of 7.5-47 nmol/L and 3.8-20 nmol/L, resp.) and inhibited cell proliferation (IC50 of 179-313 nmol/L).  PF-04691502 inhibited mTORC1 activity in cells as measured by PI3K-independent nutrient stimulated assay, with an IC50 of 32 nmol/L and inhibited the activation of PI3K and mTOR downstream effectors including AKT, FKHRL1, PRAS40, p70S6K, 4EBP1, and S6RP.  Short-term exposure to PF-04691502 predominantly inhibited PI3K, whereas mTOR inhibition persisted for 24 to 48 h.  PF-04691502 induced cell cycle G1 arrest, concomitant with upregulation of p27 Kip1 and redn. of Rb.  Antitumor activity was obsd. in U87 (PTEN null), SKOV3 (PIK3CA mutation), and gefitinib- and erlotinib-resistant non-small cell lung carcinoma xenografts.  In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity.  PF-04691502 has entered phase I clin. trials.  Mol Cancer Ther; 10(11); 2189-99.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQbgF6Nz1KLVg90H21EOLACvtfcHk0lhzpMPXVxrZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7M&md5=d9f8ba9118729c7a9c640ac5f1ae8817</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0185%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DNickel%26aufirst%3DJ.%26aulast%3DEngebretsen%26aufirst%3DJ.%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DBlasina%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMcHarg%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKan%26aufirst%3DJ.%2BL.%2BC.%26aulast%3DBagrodia%26aufirst%3DS.%26atitle%3DPF-04691502%252C%2520a%2520Potent%2520and%2520Selective%2520Oral%2520Inhibitor%2520of%2520PI3K%2520and%2520mTOR%2520Kinases%2520with%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2189%26epage%3D2199%26doi%3D10.1158%2F1535-7163.MCT-11-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the Reversible Inhibition of Enzyme-catalyzed Reactions by Tight-binding Inhibitors</span>. <i>Biochim. Biophys. Acta, Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(69)90420-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2F0005-2744%2869%2990420-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=4980133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1969&pages=269-286&author=J.+F.+Morrison&title=Kinetics+of+the+Reversible+Inhibition+of+Enzyme-catalyzed+Reactions+by+Tight-binding+Inhibitors&doi=10.1016%2F0005-2744%2869%2990420-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-86</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">A theoretical kinetic study has been undertaken to det. the kinetic characteristics of enzymic reactions that are reversibly inhibited by a substrate analog. at concns. comparable to that of the enzyme.  A general rate equation, that allows for the combination of such a tight-binding inhibitor with one or more enzyme forms of any reaction mechanism, has been derived and shown to be quadratic with sq. and linear terms in υ which represents the true initial steady-state velocity.  From plots of υ against total enzyme concn. at fixed total inhibitor concn., the concn. of enzyme catalytic sites can be detd. irrespective of the nature of the inhibition and the reaction mechanism.  However, plots of υ (or I/υ) against total inhibitor concn. can be used for this purpose only if the dissocn. const. assocd. with the inhibitor is virtually zero.  Particular initial rate equations have been obtained for the cases in which the tight-binding inhibitor gives rise to competitive, noncompetitive, and uncompetitive inhibition with respect to one of the substrates of a bireactant mechanism.  From these equations it has been deduced that, in the presence of inhibitor, plots of I/υ against the reciprocals of the substrate concns. yield families of concave-down, nonrectangular hyperbolas.  The difficulties assocd. with the detn. of inhibition consts. for tight-binding inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4s_N2iV3CLVg90H21EOLACvtfcHk0lhzpMPXVxrZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D&md5=74d467477385488dfbb053358534ada6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2869%2990420-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252869%252990420-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26atitle%3DKinetics%2520of%2520the%2520Reversible%2520Inhibition%2520of%2520Enzyme-catalyzed%2520Reactions%2520by%2520Tight-binding%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Enzymol.%26date%3D1969%26volume%3D185%26spage%3D269%26epage%3D286%26doi%3D10.1016%2F0005-2744%2869%2990420-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakala, M. T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Methods for Estimating the Dissociation Constant of Tight Binding Enzyme Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">12104</span>– <span class="NLM_lpage">12109</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2FS0021-9258%2819%2986435-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=500698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaL3cXitlem" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=12104-12109&author=W.+R.+Grecoauthor=M.+T.+Hakala&title=Evaluation+of+Methods+for+Estimating+the+Dissociation+Constant+of+Tight+Binding+Enzyme+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors</span></div><div class="casAuthors">Greco, William R.; Hakala, Maire T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12104-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A Monte Carlo simulation was used to compare 11 methods for estg. the Ki of tight binding enzyme inhibitors.  The methods were evaluated for both accuracy and precision.  Parameters were chosen to simulate the inhibition of dihydrofolate reductase by methotrexate, using dihydrofolate as substrate.  These parameters were: Ki, 100 pM; turnover no., 500/min; molar equivalency of enzyme, 400 pM/unit; dihydrofolate concn., 50 μM; and Km, 0.5 μM.  Inputs of total enzyme concn. (Et) and total inhibitor concn. (It) were chosen to keep the value of Et/Ki between 4 and 20 and to allow estn. of the concn. of the inhibitor causing 50% inhibition (I50) at each Et.  Four types of error were introduced into the simulated data: small abs., large abs., small relative, and large relative error.  Computer methods based on the equations of W. W. Ackermann and V. R. Potter (1949) and J. F. Morrison (1969) which utilized nonlinear regression, proved to be significantly more precise than the methods which would require the use of only pencil and paper.  Based on these findings a review of the published Ki values for the inhibition of dihydrofolate reductase by methotrexate is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqahqxjd5cipLVg90H21EOLACvtfcHk0lhFB_Fu5fFTIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXitlem&md5=b238cb9e286f95a348838d70cb9908f1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2986435-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252986435-9%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DW.%2BR.%26aulast%3DHakala%26aufirst%3DM.%2BT.%26atitle%3DEvaluation%2520of%2520Methods%2520for%2520Estimating%2520the%2520Dissociation%2520Constant%2520of%2520Tight%2520Binding%2520Enzyme%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D12104%26epage%3D12109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of PF-06843195. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0369. <a href="https://doi.org/10.1055/s-0040-1720321" title="DOI URL">https://doi.org/10.1055/s-0040-1720321</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1720321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1720321%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BPF-06843195%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D04%26spage%3D0369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structurally diverse PI3Kα inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of <b>4</b> bound in PI3Kα (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71">7K71</a>). The yellow dashed lines indicate H-bond interactions, and the white dashed line indicates measured distance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>10</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O">7K6O</a>). The yellow dashed lines indicate H-bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>11</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a>). The yellow dashed lines indicate H-bond interactions. Hydrophobicity surface is shown for the binding site. The yellow color indicates hydrophobic surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pairwise comparison of PI3Kα <i>K</i><sub>i</sub> for (<i>S</i>)-pyrrolidines (red) and (<i>S</i>)-C(3)-methyl pyrrolidines linker (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dihydropyrrolopyrimidine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) <i>n</i>BuLi, tetrahydrofuran (THF); 6 N HCl, 83%; (b) diisopropylethylamine (DIEA), <i>N</i>-methylpyrrolidine (NMP), 130 °C (R<sup>1</sup> = H: ∼50%, R<sup>1</sup> = Me: 80%); (c) (i) MsCl, Et<sub>3</sub>N, dimethylaminopyridine (DMAP), dichloromethane (DCM), 0 °C to room temperature (RT); (ii) <i>N</i>,<i>N</i>′-dimethylformamide (DMF), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 55–80 °C (R<sup>1</sup> = H: 78% over two steps, R<sup>1</sup> = Me: 90% over two steps); (d) R<sup>1</sup> = H: Pd(dppf)Cl<sub>2</sub>, CsF, dioxane, water, 100 °C, microwave, 87%; R<sup>1</sup> = Me: Pd(dppf)Cl<sub>2</sub>, NaHCO<sub>3</sub>, dioxane, water, 130 °C, microwave, 80%; (e) HCl, dioxane, RT (R<sup>1</sup> = H, >99%, R<sup>1</sup> = Me, >99%); (f) R<sup>3</sup>–X; see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Supporting Information</a>.</p></p></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Modeled bound conformation of 28 based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a>. The yellow dashed lines indicate H-bond interactions and the white dashed line indicates measured distance. The electrostatic potential surface is shown for the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of <b>1</b> bound in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M">7K6M</a>). The dashed lines represent H-bond interactions; yellow color indicates classical H-bond interactions, and blue color indicates a H bond between an activated C–H and a polar atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimidine Compounds<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>b</sup></span>Conditions: (a) DIEA, NMP, 70 °C (R<sup>1</sup> = Me, R<sup>2</sup> = H: 62%; R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F, 74%); (b); Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, water, 120 °C, 66% (R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F); (c) HCl, dioxane, >99%; (d) R<sup>3</sup>–X; see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf" class="ext-link">Supporting Information</a>; (e) 2,2-difluoroethanol, carbonyldiimide (CDI), Et<sub>3</sub>N, DCM, 0 °C to RT, 77%; (f) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, <i>n</i>-butanol, water 100 °C; (R<sup>1</sup> = CH<sub>2</sub>OH, R<sup>2</sup> = F, 80%).</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Phosphate Ester Formation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/medium/jm0c01652_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. LipE summary for lead development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01652/20210107/images/large/jm0c01652_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01652&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+Evolution+of+Phosphatidylinositol+3-Kinases+as+Regulators+of+Growth+and+Metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0ljSr-xN71FPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Evolution%2520of%2520Phosphatidylinositol%25203-Kinases%2520as%2520Regulators%2520of%2520Growth%2520and%2520Metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">The PI3K Pathway in Human Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.cell.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=28802037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=605-635&author=D.+A.+Frumanauthor=H.+Chiuauthor=B.+D.+Hopkinsauthor=S.+Bagrodiaauthor=L.+C.+Cantleyauthor=R.+T.+Abraham&title=The+PI3K+Pathway+in+Human+Disease&doi=10.1016%2Fj.cell.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway in Human Disease</span></div><div class="casAuthors">Fruman, David A.; Chiu, Honyin; Hopkins, Benjamin D.; Bagrodia, Shubha; Cantley, Lewis C.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-635</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer.  Many PI3K pathway-targeted therapies have been tested in oncol. trials, resulting in regulatory approval of one isoform-selective inhibitor (idelalisib) for treatment of certain blood cancers and a variety of other agents at different stages of development.  In parallel to PI3K research by cancer biologists, investigations in other fields have uncovered exciting and often unpredicted roles for PI3K catalytic and regulatory subunits in normal cell function and in disease.  Many of these functions impinge upon oncol. by influencing the efficacy and toxicity of PI3K-targeted therapies.  Here we provide a perspective on the roles of class I PI3Ks in the regulation of cellular metab. and in immune system functions, two topics closely intertwined with cancer biol.  We also discuss recent progress developing PI3K-targeted therapies for treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1NPtgicD_rVg90H21EOLACvtfcHk0ljSr-xN71FPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL&md5=a5a5c06960587cefa95a6fb8cc647c7f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DThe%2520PI3K%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D605%26epage%3D635%26doi%3D10.1016%2Fj.cell.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">High Frequency of Mutations of the PIK3CA Gene in Human Cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">554</span>, <span class="refDoi"> DOI: 10.1126/science.1096502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptakauthor=S.+Szaboauthor=H.+Yanauthor=A.+Gazdarauthor=S.+M.+Powellauthor=G.+J.+Rigginsauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=High+Frequency+of+Mutations+of+the+PIK3CA+Gene+in+Human+Cancers&doi=10.1126%2Fscience.1096502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0lheUNCuDhGtNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DHigh%2520Frequency%2520of%2520Mutations%2520of%2520the%2520PIK3CA%2520Gene%2520in%2520Human%2520Cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D554%26doi%3D10.1126%2Fscience.1096502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-13-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24748656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1021-1031&author=R.+Dienstmannauthor=J.+Rodonauthor=V.+Serraauthor=J.+Tabernero&title=Picking+the+Point+of+Inhibition%3A+A+Comparative+Review+of+PI3K%2FAKT%2FmTOR+Pathway+Inhibitors&doi=10.1158%2F1535-7163.MCT-13-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors</span></div><div class="casAuthors">Dienstmann, Rodrigo; Rodon, Jordi; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1031</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacol. intervention.  Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the no. of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clin. investigation.  These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K" inhibitors, which inhibit all four isoforms of class I PI3K (α, β, δ, γ); isoform-specific inhibitors of the various PI3K isoforms; allosteric and catalytic inhibitors of AKT; and ATP-competitive inhibitors of mTOR only (and thus mTORC1 and mTORC2).  With so many agents in development, clinicians are currently faced with a wide array of clin. trials investigating a multitude of inhibitors with different mechanisms of action, being used both as single agents and in combination with other therapies.  Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity.  Mol Cancer Ther; 13(5); 1021-31. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3McPbkS5dm7Vg90H21EOLACvtfcHk0ljqKOujA2R52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjs78%253D&md5=7b5ef12e83be522233ad403ce3040719</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0639%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DPicking%2520the%2520Point%2520of%2520Inhibition%253A%2520A%2520Comparative%2520Review%2520of%2520PI3K%252FAKT%252FmTOR%2520Pathway%2520Inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1021%26epage%3D1031%26doi%3D10.1158%2F1535-7163.MCT-13-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4815</span>– <span class="NLM_lpage">4850</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01492</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01492" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4815-4850&author=A.+E.+Garcesauthor=M.+J.+Stocks&title=Class+1+PI3K+Clinical+Candidates+and+Recent+Inhibitor+Design+Strategies%3A+A+Medicinal+Chemistry+Perspective&doi=10.1021%2Facs.jmedchem.8b01492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Garces, Aimie E.; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4815-4850</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases.  The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chem. with over 600 medicinal chem.-based publications and patents appearing to date, leading to 38 clin. candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017.  This Perspective will discuss medicinal chem. design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compds. that have progressed into clin. development or that have revealed new structural motifs in this highly competitive area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUu2mgndklHbVg90H21EOLACvtfcHk0ljqKOujA2R52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOku7bK&md5=907395a39ed6fb683464ee92c6a2537f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DClass%25201%2520PI3K%2520Clinical%2520Candidates%2520and%2520Recent%2520Inhibitor%2520Design%2520Strategies%253A%2520A%2520Medicinal%2520Chemistry%2520Perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4815%26epage%3D4850%26doi%3D10.1021%2Facs.jmedchem.8b01492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Tomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trandafir, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span> <span> </span><span class="NLM_article-title">Phase I Dose-Escalation and -Expansion Study of Buparlisib (BKM120), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">670</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0082-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1007%2Fs10637-014-0082-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24652201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=670-681&author=J.+Rodonauthor=I.+Branaauthor=L.+L.+Siuauthor=M.+J.+De+Jongeauthor=N.+Homjiauthor=D.+Millsauthor=E.+Di+Tomasoauthor=C.+Sarrauthor=L.+Trandafirauthor=C.+Massacesiauthor=F.+Eskensauthor=J.+C.+Bendell&title=Phase+I+Dose-Escalation+and+-Expansion+Study+of+Buparlisib+%28BKM120%29%2C+an+Oral+Pan-Class+I+PI3K+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors.&doi=10.1007%2Fs10637-014-0082-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Rodon, Jordi; Brana, Irene; Siu, Lillian L.; De Jonge, Maja J.; Homji, Natasha; Mills, David; Di Tomaso, Emmanuelle; Sarr, Celine; Trandafir, Lucia; Massacesi, Cristian; Eskens, Ferry; Bendell, Johanna C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">670-681</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose The pan-Class I PI3K inhibitor buparlisib (BKM120) has shown activity in a range of preclin. cancer models.  This first-in-man study was initiated to identify the max. tolerated dose (MTD) of buparlisib (100 mg/day) and to assess safety and preliminary efficacy.  Methods Patients with advanced solid tumors (N = 83) enrolled in a Phase I dose-escalation and -expansion study of single-agent buparlisib.  Patients in the dose-expansion arm (n = 43) had tumor samples with PIK3CA and/or PTEN alterations.  Results The most common cancers were colorectal (n = 31) and breast cancer (n = 21).  Median no. of prior antineoplastic regimens was four (range: 1-12).  Grade 3/4 adverse events (AEs) included asthenia (12.0 %) and performance status decrease (9.6 %).  Treatment-related AEs (all grades) included decreased appetite, diarrhea, nausea (each in 33 % of patients), hyperglycemia (31 %) and rash (29 %).  One confirmed partial response (PR; triple-neg. breast cancer) and three unconfirmed PRs (parotid gland carcinoma, epithelioid hemangiothelioma, ER + breast cancer) were reported.  Tumor mol. status did not predict clin. benefit in the full study cohort, or among the colorectal or breast cancer subpopulations.  Pharmacodynamic biomarkers (18F-FDG-PET, C-peptide, pS6) demonstrated dose-dependent changes; however, tumor heterogeneity precluded a clear correlation with clin. benefit.  Conclusion Buparlisib was well tolerated up to the 100 mg/day dose and showed preliminary activity in patients with advanced cancers.  Future studies in more homogeneous patient populations will evaluate buparlisib in combination with other agents and further investigate the use of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9JLgQd5SixbVg90H21EOLACvtfcHk0liK1V02roR30g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vO&md5=78ad3de32e7118c465ad608a05ae6712</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0082-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0082-9%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DBrana%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%26aulast%3DHomji%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DD.%26aulast%3DDi%2BTomaso%26aufirst%3DE.%26aulast%3DSarr%26aufirst%3DC.%26aulast%3DTrandafir%26aufirst%3DL.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3DEskens%26aufirst%3DF.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520I%2520Dose-Escalation%2520and%2520-Expansion%2520Study%2520of%2520Buparlisib%2520%2528BKM120%2529%252C%2520an%2520Oral%2520Pan-Class%2520I%2520PI3K%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors.%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D670%26epage%3D681%26doi%3D10.1007%2Fs10637-014-0082-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G.</span></span> <span> </span><span class="NLM_article-title">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1078-0432.CCR-13-1777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24166903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=233-245&author=G.+I.+Shapiroauthor=J.+Rodonauthor=C.+Bedellauthor=E.+L.+Kwakauthor=J.+Baselgaauthor=I.+Branaauthor=S.+S.+Pandyaauthor=C.+Scheffoldauthor=A.+D.+Lairdauthor=L.+T.+Nguyenauthor=Y.+Xuauthor=C.+Egileauthor=G.+Edelman&title=Phase+I+Safety%2C+Pharmacokinetic%2C+and+Pharmacodynamic+Study+of+SAR245408+%28XL147%29%2C+an+Oral+Pan-Class+I+PI3K+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-1777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shapiro, Geoffrey I.; Rodon, Jordi; Bedell, Cynthia; Kwak, Eunice L.; Baselga, Jose; Brana, Irene; Pandya, Shuchi S.; Scheffold, Christian; Laird, A. Douglas; Nguyen, Linh T.; Xu, Yi; Egile, Coumaran; Edelman, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: SAR245408 is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor.  This phase I study detd. the max. tolerated dose (MTD) of two dosing schedules [first 21 days of a 28-day period (21/7) and continuous once-daily dosing (CDD)], pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy.  Exptl. Design: Patients with refractory advanced solid malignancies were treated with SAR245408 using a 3 + 3 design.  Pharmacokinetic parameters were detd. after single and repeated doses.  Pharmacodynamic effects were evaluated in plasma, hair sheath cells, and skin and tumor biopsies.  Results: Sixty-nine patients were enrolled.  The MTD of both schedules was 600 mg; dose-limiting toxicities were maculopapular rash and hypersensitivity reaction.  The most frequent drug-related adverse events included dermatol. toxicities, diarrhea, nausea, and decreased appetite.  Plasma pharmacokinetics showed a median time to max. concn. of 8 to 22 h, mean terminal elimination half-life of 70 to 88 h, and 5- to 13-fold accumulation after daily dosing (first cycle).  Steady-state concn. was reached between days 15 and 21, and exposure was dose-proportional with doses up to 400 mg.  SAR245408 inhibited the PI3K pathway (∼40%-80% redn. in phosphorylation of AKT, PRAS40, 4EBP1, and S6 in tumor and surrogate tissues) and, unexpectedly, also inhibited the MEK/ERK pathway.  A partial response was seen in one patient with advanced non-small cell lung cancer.  Eight patients were progression-free at 6 mo.  Pharmacodynamic and clin. activity were obsd. irresp. of tumor PI3K pathway mol. alterations.  Conclusions: SAR245408 was tolerable at doses assocd. with PI3K pathway inhibition.  The recommended phase II dose of the capsule formulation is 600 mg administered orally with CDD.  Clin Cancer Res; 20(1); 233-45. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBJvsX9x4E-7Vg90H21EOLACvtfcHk0liK1V02roR30g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKksQ%253D%253D&md5=1f692dba8f960c733722f1956ebf2f50</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1777%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DBedell%26aufirst%3DC.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBrana%26aufirst%3DI.%26aulast%3DPandya%26aufirst%3DS.%2BS.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DEgile%26aufirst%3DC.%26aulast%3DEdelman%26aufirst%3DG.%26atitle%3DPhase%2520I%2520Safety%252C%2520Pharmacokinetic%252C%2520and%2520Pharmacodynamic%2520Study%2520of%2520SAR245408%2520%2528XL147%2529%252C%2520an%2520Oral%2520Pan-Class%2520I%2520PI3K%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D233%26epage%3D245%26doi%3D10.1158%2F1078-0432.CCR-13-1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrickson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">First-in-human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+Phase+I+Study+of+Pictilisib+%28GDC-0941%29%2C+a+Potent+Pan-Class+I+Phosphatidylinositol-3-Kinase+%28PI3K%29+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 h·μmol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels ≥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lg_xIhF_S9X1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520Phase%2520I%2520Study%2520of%2520Pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520Potent%2520Pan-Class%2520I%2520Phosphatidylinositol-3-Kinase%2520%2528PI3K%2529%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozeboom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozeboom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span> <span> </span><span class="NLM_article-title">ER+ Metastatic Breast Cancer: Past, Present, and a Prescription for an Apoptosis-targeted Future</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2821</span>– <span class="NLM_lpage">2831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=31911865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtValt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=2821-2831&author=B.+Rozeboomauthor=N.+Deyauthor=P.+Deauthor=B.+Rozeboomauthor=N.+Deyauthor=P.+Deauthor=P.+De&title=ER%2B+Metastatic+Breast+Cancer%3A+Past%2C+Present%2C+and+a+Prescription+for+an+Apoptosis-targeted+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future</span></div><div class="casAuthors">Rozeboom, Brett; Dey, Nandini; De, Pradip</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2821-2831</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">The importance and role of the estrogen receptor (ER) pathway have been well-recognized in both breast cancer development and progression.  The treatment of choice in women with estrogen receptor-pos. metastatic breast cancer (ER+ mBC) is classically divided into a variety of endocrine therapies, with three of the most common being: selective estrogen receptor modulators (SERM), aromatase inhibitors (AI), and selective estrogen receptor degraders (SERD).  However, resistance develops in 30-50% of patients treated with these endocrine therapies due to a sophisticated and at times redundant interference at the mol. level between the ER, growth factors, and downstream cell-signaling pathways.  Tumor response is heightened with adjunctive therapy that includes an mTORC1 inhibitor (everolimus), CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib), and an a isoform-specifi PI3K inhibitor (alpelisib).  Each of these inhibitors elicits potent anti-proliferative benefis; however, they fail to induce tumor cell death.  Consequently, disease progression almost invariably occurs.  Evasion of apoptosis is a hallmark of cancer.  The p53 and BCL2 represent two important nodes of the apoptosis signaling pathway.  Venetoclax, a potent and selective BCL2 inhibitor, synergizes with hormonal therapy in ER+ breast cancer models and is active in clin. trials.  Similarly, an MDM2 inhibitor, AMG-232, which induces p53 is active in early clin. trials of both liq. and advanced solid tumor patients.  In our ER+ BC cohort (Avera Cancer Institute, Sioux Falls, SD), we obsd. more than 70% of wild type TP53 and over 10% amplifiation of MDM2 and MDM4 as comparable with the TCGA data set.  We summarized current treatment options, the mol. mechanisms that predispose to endocrine resistance, and a future pro-apoptotic treatment strategy for ER+ mBC patients.  Our review presents crit. analyses of the therapeutic options for the clin. management of ER+ Metastatic Breast Cancer in the light of a hypothesis targeting the induction of apoptosis in p53 wild type tumors.  We reviewed not only the FDA approved current treatment approaches but also presented a discourse addressing the possibilities for novel combination strategy that can induce tumor cell apoptosis, a crit. cellular mechanism delaying/denying tumor progression.  Our review is unique as it presents patient data in support of our hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6rjMDMCoKLVg90H21EOLACvtfcHk0lg_xIhF_S9X1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtValt7rI&md5=d71fe9f29e40e2e4a4895921f4df1ae7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRozeboom%26aufirst%3DB.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DRozeboom%26aufirst%3DB.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DDe%26aufirst%3DP.%26atitle%3DER%252B%2520Metastatic%2520Breast%2520Cancer%253A%2520Past%252C%2520Present%252C%2520and%2520a%2520Prescription%2520for%2520an%2520Apoptosis-targeted%2520Future%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2019%26volume%3D9%26spage%3D2821%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase α-Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results from the First-in-human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+%CE%B1-Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+PIK3CA-Altered+Solid+Tumors%3A+Results+from+the+First-in-human+Study&doi=10.1200%2FJCO.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0lhrs20ysOrE9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520%25CE%25B1-Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520PIK3CA-Altered%2520Solid%2520Tumors%253A%2520Results%2520from%2520the%2520First-in-human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2FJCO.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatenay-Rivauday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=P.+A.+Deauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.-M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+Novel+and+Specific+PI3K%CE%B1+Inhibitor+NVP-BYL719+and+Development+of+the+Patient+Stratification+Strategy+for+Clinical+Trials&doi=10.1158%2F1535-7163.MCT-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0lhrs20ysOrE9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DP.%2BA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520and%2520Specific%2520PI3K%25CE%25B1%2520Inhibitor%2520NVP-BYL719%2520and%2520Development%2520of%2520the%2520Patient%2520Stratification%2520Strategy%2520for%2520Clinical%2520Trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.MCT-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M.-G.</span>; <span class="NLM_string-name">Chan, C.</span>; <span class="NLM_string-name">Clausen, S.</span>; <span class="NLM_string-name">Edgar, K.</span>; <span class="NLM_string-name">Eigenbrot, C.</span>; <span class="NLM_string-name">Eliott, R.</span>; <span class="NLM_string-name">Endres, N.</span>; <span class="NLM_string-name">Friedman, L.</span>; <span class="NLM_string-name">Gerland, K.</span>; <span class="NLM_string-name">Gu, X.-H.</span>; <span class="NLM_string-name">Hamilton, P.</span>; <span class="NLM_string-name">Han, C.</span>; <span class="NLM_string-name">Hanan, E.</span>; <span class="NLM_string-name">Hong, R.</span>; <span class="NLM_string-name">Jackson, P.</span>; <span class="NLM_string-name">Kelly, S.</span>; <span class="NLM_string-name">Knight, J.</span>; <span class="NLM_string-name">Lee, M.-L.</span>; <span class="NLM_string-name">Lu, A.</span>; <span class="NLM_string-name">MacLeod, C.</span>; <span class="NLM_string-name">McKenzie, A.</span>; <span class="NLM_string-name">Nannini, M.</span>; <span class="NLM_string-name">Narukulla, R.</span>; <span class="NLM_string-name">Nguyen, A.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Purkey, H.</span>; <span class="NLM_string-name">Salphati, L.</span>; <span class="NLM_string-name">Sampath, D.</span>; <span class="NLM_string-name">Schmidt, S.</span>; <span class="NLM_string-name">Schutt, L.</span>; <span class="NLM_string-name">Heald, R.</span>; <span class="NLM_string-name">Song, K.</span>; <span class="NLM_string-name">Ultsch, M.</span>; <span class="NLM_string-name">Xin, J.</span>; <span class="NLM_string-name">Yeap, K.</span>; <span class="NLM_string-name">Young, A.</span>; <span class="NLM_string-name">Zhong, Z.</span>; <span class="NLM_string-name">Staben, S.</span></span> <i>Discovery of GDC-0077: A Highly Selective Inhibitor of PI3K-Alpha That Induces Degradation of Mutant-p110 Alpha Protein</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2017</span>; p  <span class="NLM_fpage">MEDI-22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=MEDI-22&author=M.-G.+Braun&author=C.+Chan&author=S.+Clausen&author=K.+Edgar&author=C.+Eigenbrot&author=R.+Eliott&author=N.+Endres&author=L.+Friedman&author=K.+Gerland&author=X.-H.+Gu&author=P.+Hamilton&author=C.+Han&author=E.+Hanan&author=R.+Hong&author=P.+Jackson&author=S.+Kelly&author=J.+Knight&author=M.-L.+Lee&author=A.+Lu&author=C.+MacLeod&author=A.+McKenzie&author=M.+Nannini&author=R.+Narukulla&author=A.+Nguyen&author=J.+Pang&author=H.+Purkey&author=L.+Salphati&author=D.+Sampath&author=S.+Schmidt&author=L.+Schutt&author=R.+Heald&author=K.+Song&author=M.+Ultsch&author=J.+Xin&author=K.+Yeap&author=A.+Young&author=Z.+Zhong&author=S.+Staben&title=Discovery+of+GDC-0077%3A+A+Highly+Selective+Inhibitor+of+PI3K-Alpha+That+Induces+Degradation+of+Mutant-p110+Alpha+Protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DM.-G.%26btitle%3DDiscovery%2520of%2520GDC-0077%253A%2520A%2520Highly%2520Selective%2520Inhibitor%2520of%2520PI3K-Alpha%2520That%2520Induces%2520Degradation%2520of%2520Mutant-p110%2520Alpha%2520Protein%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2017%26spage%3DMEDI-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Monomeric Targeted Protein Degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11330</span>– <span class="NLM_lpage">11361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotl2qsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11330-11361&author=E.+J.+Hananauthor=J.+Liangauthor=X.+Wangauthor=R.+Blakeauthor=N.+Blaquiereauthor=S.+T.+Staben&title=Monomeric+Targeted+Protein+Degraders&doi=10.1021%2Facs.jmedchem.0c00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Monomeric Targeted Protein Degraders</span></div><div class="casAuthors">Hanan, Emily J.; Liang, Jun; Wang, Xiaojing; Blake, Robert A.; Blaquiere, Nicole; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11330-11361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chem.  Inducing degrdn. of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacol.  While engineered heterodimeric mols. have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degrdn. obsd. for smaller, monomeric mols.  Methods and tools for evaluating protein degrdn. as well as a discussion of phys. properties of monomeric vs engineered heterodimeric degraders are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqys0SNWcaCTLVg90H21EOLACvtfcHk0lgiyMlflYOiUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotl2qsbY%253D&md5=bd4c3240f66ef2f7611fdffde6ec5c3a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DMonomeric%2520Targeted%2520Protein%2520Degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11330%26epage%3D11361%26doi%3D10.1021%2Facs.jmedchem.0c00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 Through Structure Based Drug Design</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1039/c0md00072h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1039%2Fc0md00072h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVansL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=139-144&author=H.+Chengauthor=S.+Bagrodiaauthor=S.+Baileyauthor=M.+Edwardsauthor=J.+Hoffmanauthor=Q.-Y.+Huauthor=R.+Kaniaauthor=D.+R.+Knightonauthor=M.+A.+Marxauthor=S.+Ninkovicauthor=S.+Sunauthor=E.+Zhang&title=Discovery+of+the+Highly+Potent+PI3K%2FmTOR+Dual+Inhibitor+PF-04691502+Through+Structure+Based+Drug+Design&doi=10.1039%2Fc0md00072h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design</span></div><div class="casAuthors">Cheng, Hengmiao; Bagrodia, Shubha; Bailey, Simon; Edwards, Martin; Hoffman, Jacqui; Hu, Qi-Yue; Kania, Robert; Knighton, Daniel R.; Marx, Matthew A.; Ninkovic, Sacha; Sun, Shaoxian; Zhang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-144</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays crucial roles in cell growth, proliferation and survival.  Genomic aberrations in the PI3K pathway, such as mutational activation of PI3Kα or loss of function of tumor suppressor PTEN, have been closely linked to the development and progression of a wide range of cancers.  Hence, inhibition of the key targets in the pathway, e.g.  PI3K, AKT, mTOR, offers great potential for the treatment of cancer.  Lead optimization through integration of structure based drug design (SBDD) and phys. properties-based optimization (PPBO) led to the discovery of 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502, 1) that demonstrated potent in vitro inhibitory activity against both PI3K and mTOR, excellent kinase selectivity, good ADMET, and robust in vivo efficacy in a mouse xenograft tumor growth model.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQLpVG9peoLVg90H21EOLACvtfcHk0lgocjzA7sUigw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVansL7P&md5=2fe2649dd9cd51fcf09ae13fa529fcb2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1039%2Fc0md00072h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00072h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.-Y.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FmTOR%2520Dual%2520Inhibitor%2520PF-04691502%2520Through%2520Structure%2520Based%2520Drug%2520Design%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D139%26epage%3D144%26doi%3D10.1039%2Fc0md00072h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-based Drug Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/ml300309h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300309h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=91-97&author=H.+Chengauthor=C.+Liauthor=S.+Baileyauthor=S.+M.+Baxiauthor=L.+Gouletauthor=L.+Guoauthor=J.+Hoffmanauthor=Y.+Jiangauthor=T.+O.+Johnsonauthor=T.+W.+Johnsonauthor=D.+R.+Knightonauthor=J.+Liauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=M.+A.+Marxauthor=M.+Wallsauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=J.+Zhuauthor=M.+Zientek&title=Discovery+of+the+Highly+Potent+PI3K%2FmTOR+Dual+Inhibitor+PF-04979064+through+Structure-based+Drug+Design&doi=10.1021%2Fml300309h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span></div><div class="casAuthors">Cheng, Hengmiao; Li, Chunze; Bailey, Simon; Baxi, Sangita M.; Goulet, Lance; Guo, Lisa; Hoffman, Jacqui; Jiang, Ying; Johnson, Theodore Otto; Johnson, Ted W.; Knighton, Daniel R.; Li, John; Liu, Kevin K.-C.; Liu, Zhengyu; Marx, Matthew A.; Walls, Marlena; Wells, Peter A.; Yin, Min-Jean; Zhu, Jinjiang; Zientek, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncol.  To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clin. trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series.  Integration of structure-based drug design and phys. properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064 (I).  This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a no. of ADMET issues including high metabolic clearance mediated by both P 450 and aldehyde oxidase (AO), poor permeability, and poor soly.  An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivs. that were AO substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsQSJqL-ssP7Vg90H21EOLACvtfcHk0lgocjzA7sUigw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I&md5=0059c9c220419aad748b4fcde92c28bb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml300309h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300309h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZientek%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FmTOR%2520Dual%2520Inhibitor%2520PF-04979064%2520through%2520Structure-based%2520Drug%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D91%26epage%3D97%26doi%3D10.1021%2Fml300309h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paderes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span> <span> </span><span class="NLM_article-title">Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1021/ml200126j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200126j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=809-813&author=K.+K.+C.+Liuauthor=J.+J.+Zhuauthor=G.+L.+Smithauthor=M.-J.+Yinauthor=S.+Baileyauthor=J.+H.+Chenauthor=Q.+Huauthor=Q.+Huangauthor=C.+Liauthor=Q.+J.+Liauthor=M.+A.+Marxauthor=G.+Paderesauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=M.+Wallsauthor=P.+A.+Wellsauthor=A.+Zou&title=Highly+Selective+and+Potent+Thiophenes+as+PI3K+Inhibitors+with+Oral+Antitumor+Activity&doi=10.1021%2Fml200126j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity</span></div><div class="casAuthors">Liu, Kevin K.-C.; Zhu, Jin Jiang; Smith, Graham L.; Yin, Min-Jean; Bailey, Simon; Chen, Jeffrey H.; Hu, Qiyue; Huang, Qinhua; Li, Chunze; Li, Qing J.; Marx, Matthew A.; Paderes, Genevieve; Richardson, Paul F.; Sach, Neal W.; Walls, Marlena; Wells, Peter A.; Baxi, Sangita; Zou, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly selective PI3K inhibitors with subnanomolar PI3Kα potency and greater than 7000-fold selectivity against mTOR kinase were discovered through structure-based drug design (SBDD).  These tetra-substituted thiophenes were also demonstrated to have good in vitro cellular potency and good in vivo oral antitumor activity in a mouse PI3K driven NCI-H1975 xenograft tumor model.  Compds. with the desired human PK predictions and good in vitro ADMET properties were also identified.  In this communication, we describe the rationale behind the installation of a crit. triazole moiety to maintain the intricate H-bonding network within the PI3K receptor leading to both better potency and selectivity.  Furthermore, optimization of the C-4 Ph group was exploited to maximize the compds. mTOR selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVf_CRUykT9bVg90H21EOLACvtfcHk0lgEe2mDG1Axwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7fL&md5=9cb3f49dfc251f6347de5e17ca8b3bba</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml200126j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200126j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%2BJ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DPaderes%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DZou%26aufirst%3DA.%26atitle%3DHighly%2520Selective%2520and%2520Potent%2520Thiophenes%2520as%2520PI3K%2520Inhibitors%2520with%2520Oral%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D809%26epage%3D813%26doi%3D10.1021%2Fml200126j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur Rogers, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Kα and mTOR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5098</span>– <span class="NLM_lpage">5103</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2012.05.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=22749419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5098-5103&author=P.+T.+Leauthor=H.+Chengauthor=S.+Ninkovicauthor=M.+Pleweauthor=X.+Huangauthor=H.+Wangauthor=S.+Bagrodiaauthor=S.+Sunauthor=D.+R.+Knightonauthor=C.+M.+LaFleur+Rogersauthor=A.+Panniferauthor=S.+Greasleyauthor=D.+Dalvieauthor=E.+Zhang&title=Design+and+Synthesis+of+a+Novel+Pyrrolidinyl+Pyrido+Pyrimidinone+Derivative+as+a+Potent+Inhibitor+of+PI3K%CE%B1+and+mTOR&doi=10.1016%2Fj.bmcl.2012.05.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR</span></div><div class="casAuthors">Le, Phuong T.; Cheng, Hengmiao; Ninkovic, Sacha; Plewe, Michael; Huang, Xiaojun; Wang, Hai; Bagrodia, Shubha; Sun, Shaoxian; Knighton, Daniel R.; LaFleur Rogers, Caroline M.; Pannifer, Andrew; Greasley, Samantha; Dalvie, Deepak; Zhang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5098-5103</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lead optimization efforts that employed structure base drug design and physicochem. property based optimization leading to the discovery of a novel series of 4-methylpyrido pyrimidinone (MPP) are discussed.  Synthesis and profile of I, a PI3Kα/mTOR dual inhibitor, is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCna8LjcDc7rVg90H21EOLACvtfcHk0lgEe2mDG1Axwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1KnsL8%253D&md5=14685f94189ea6f4571f061f6e2c4d1b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNinkovic%26aufirst%3DS.%26aulast%3DPlewe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLaFleur%2BRogers%26aufirst%3DC.%2BM.%26aulast%3DPannifer%26aufirst%3DA.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Pyrrolidinyl%2520Pyrido%2520Pyrimidinone%2520Derivative%2520as%2520a%2520Potent%2520Inhibitor%2520of%2520PI3K%25CE%25B1%2520and%2520mTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5098%26epage%3D5103%26doi%3D10.1016%2Fj.bmcl.2012.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahavendran, S. V.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design, SAR Analysis and Antitumor Activity of PI3K/mTOR Dual Inhibitors from 4-Methylpyridopyrimidinone Series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2013.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=23506825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlGntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2787-2792&author=H.+Chengauthor=J.+E.+Hoffmanauthor=P.+T.+Leauthor=M.+Pairishauthor=R.+Kaniaauthor=W.+Farrellauthor=S.+Bagrodiaauthor=J.+Yuanauthor=S.+Sunauthor=E.+Zhangauthor=C.+Xiangauthor=D.+Dalvieauthor=S.+V.+Rahavendran&title=Structure-based+Design%2C+SAR+Analysis+and+Antitumor+Activity+of+PI3K%2FmTOR+Dual+Inhibitors+from+4-Methylpyridopyrimidinone+Series&doi=10.1016%2Fj.bmcl.2013.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series</span></div><div class="casAuthors">Cheng, Hengmiao; Hoffman, Jacqui E.; Le, Phuong T.; Pairish, Mason; Kania, Robert; Farrell, William; Bagrodia, Shubha; Yuan, Jing; Sun, Shaoxian; Zhang, Eric; Xiang, Cathy; Dalvie, Deepak; Rahavendran, Sadayappan V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2787-2792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3K, AKT and mTOR, key kinases from a frequently dysregulated PI3K signaling pathway, have been extensively pursued to treat a variety of cancers in oncol.  Clin. trials of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR, from 4-methylpyridopyrimidinone series, led to the discovery of a metabolite with a terminal carboxylic acid, PF-06465603.  This paper discusses structure-based drug design, SAR and antitumor activity of the MPP derivs. with a terminal alc., a carboxylic acid or a carboxyl amide e. g., I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXKbI5bhsyd7Vg90H21EOLACvtfcHk0lgEe2mDG1Axwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlGntL4%253D&md5=f0a588adb95f94f9c952ced10f91f2b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DW.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DRahavendran%26aufirst%3DS.%2BV.%26atitle%3DStructure-based%2520Design%252C%2520SAR%2520Analysis%2520and%2520Antitumor%2520Activity%2520of%2520PI3K%252FmTOR%2520Dual%2520Inhibitors%2520from%25204-Methylpyridopyrimidinone%2520Series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2787%26epage%3D2792%26doi%3D10.1016%2Fj.bmcl.2013.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and Biological Activity of a Novel Class I PI3K Inhibitor, CH5132799</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2011.01.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=21316229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslKjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1767-1772&author=J.+Ohwadaauthor=H.+Ebiikeauthor=H.+Kawadaauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=T.+Miyazakiauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=O.+Kondohauthor=S.+Kuramotoauthor=K.+Ogawaauthor=Y.+Aokiauthor=N.+Shimma&title=Discovery+and+Biological+Activity+of+a+Novel+Class+I+PI3K+Inhibitor%2C+CH5132799&doi=10.1016%2Fj.bmcl.2011.01.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799</span></div><div class="casAuthors">Ohwada, Jun; Ebiike, Hirosato; Kawada, Hatsuo; Tsukazaki, Masao; Nakamura, Mitsuaki; Miyazaki, Takuya; Morikami, Kenji; Yoshinari, Kiyoshi; Yoshida, Miyuki; Kondoh, Osamu; Kuramoto, Shino; Ogawa, Kotaro; Aoki, Yuko; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1767-1772</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer.  Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton.  Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety.  CH5132799 (I), a novel class I PI3K inhibitor, exhibited a strong inhibitory activity esp. against PI3Kα (IC50 = 0.014 μM).  In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity.  CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4CnvKaeZRFrVg90H21EOLACvtfcHk0ljopIdSwykLrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslKjsLw%253D&md5=502b8e8430388cc5a0ef548859f7294a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520Biological%2520Activity%2520of%2520a%2520Novel%2520Class%2520I%2520PI3K%2520Inhibitor%252C%2520CH5132799%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1767%26epage%3D1772%26doi%3D10.1016%2Fj.bmcl.2011.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Class+I+PI3+Kinase+Inhibitor+for+Treating+Cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0ljopIdSwykLrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Class%2520I%2520PI3%2520Kinase%2520Inhibitor%2520for%2520Treating%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kestell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, S. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7105</span>– <span class="NLM_lpage">7126</span>, <span class="refDoi"> DOI: 10.1021/jm200688y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200688y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7105-7126&author=G.+W.+Rewcastleauthor=S.+A.+Gamageauthor=J.+U.+Flanaganauthor=R.+Frederickauthor=W.+A.+Dennyauthor=B.+C.+Baguleyauthor=P.+Kestellauthor=R.+Singhauthor=J.+D.+Kendallauthor=E.+S.+Marshallauthor=C.+L.+Lillauthor=W.-J.+Leeauthor=S.+Kolekarauthor=C.+M.+Buchananauthor=S.+M.+F.+Jamiesonauthor=P.+R.+Shepherd&title=Synthesis+and+Biological+Evaluation+of+Novel+Analogues+of+the+Pan+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitor+2-%28Difluoromethyl%29-1-%5B4%2C6-di%284-morpholinyl%29-1%2C3%2C5-triazin-2-yl%5D-1H-benzimidazole+%28ZSTK474%29&doi=10.1021%2Fjm200688y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-Kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)</span></div><div class="casAuthors">Rewcastle, Gordon W.; Gamage, Swarna A.; Flanagan, Jack U.; Frederick, Raphael; Denny, William A.; Baguley, Bruce C.; Kestell, Philip; Singh, Ripudaman; Kendall, Jackie D.; Marshall, Elaine S.; Lill, Claire L.; Lee, Woo-Jeong; Kolekar, Sharada; Buchanan, Christina M.; Jamieson, Stephen M. F.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7105-7126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) I identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivs.  The 6-amino-4-methoxy analog II displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy III analog against all three class Ia PI 3-kinase enzymes (p110α, p110β, and p110δ) and also displayed significant potency against two mutant forms of the p110α isoform (H1047R and E545K).  This compd. was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1-/- mice, and at a dose of 50 mg/kg given by i.p. injection at a qd × 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirsalawdjHrVg90H21EOLACvtfcHk0lhRd13C6WR8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7rJ&md5=250fb3eeb02505e2a5b24fd511ec94f3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm200688y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200688y%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%2BF.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Analogues%2520of%2520the%2520Pan%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%25202-%2528Difluoromethyl%2529-1-%255B4%252C6-di%25284-morpholinyl%2529-1%252C3%252C5-triazin-2-yl%255D-1H-benzimidazole%2520%2528ZSTK474%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7105%26epage%3D7126%26doi%3D10.1021%2Fjm200688y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrit, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weismann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-Kinase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/ml1001932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yhsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=34-38&author=M.+T.+Burgerauthor=M.+Knappauthor=A.+Wagmanauthor=Z.-J.+Niauthor=T.+Hendricksonauthor=G.+Atallahauthor=Y.+Zhangauthor=K.+Frazierauthor=J.+Verhagenauthor=K.+Pfisterauthor=S.+Ngauthor=A.+Smithauthor=S.+Bartulisauthor=H.+Merritauthor=M.+Weismannauthor=X.+Xinauthor=J.+Haznedarauthor=C.+F.+Volivaauthor=E.+Iwanowiczauthor=S.+Pecchi&title=Synthesis+and+in+Vitro+and+in+Vivo+Evaluation+of+Phosphoinositide-3-Kinase+Inhibitors&doi=10.1021%2Fml1001932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors</span></div><div class="casAuthors">Burger, Matthew T.; Knapp, Mark; Wagman, Allan; Ni, Zhi-Jie; Hendrickson, Thomas; Atallah, Gordana; Zhang, Yanchen; Frazier, Kelly; Verhagen, Joelle; Pfister, Keith; Ng, Simon; Smith, Aaron; Bartulis, Sarah; Merrit, Hanne; Weismann, Marion; Xin, Xiaohua; Haznedar, Joshua; Voliva, Charles F.; Iwanowicz, Ed; Pecchi, Sabina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3K) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  A series of 2-morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks.  Herein, we describe the structure-guided optimization of these pyrimidines with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties.  A series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines, which potently inhibit PI3K, were discovered.  Within this series a compd. (I) was identified with suitable pharmacokinetic (PK) properties, which allowed for the establishment of a PI3K PK/pharmacodynamic-efficacy relationship as detd. by in vivo inhibition of AKTSer473 phosphorylation and tumor growth inhibition in a mouse A2780 tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFT_jbWymff7Vg90H21EOLACvtfcHk0lhRd13C6WR8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yhsLzM&md5=887fc3a37de2a495a9edceaa00a251f7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fml1001932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001932%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DMerrit%26aufirst%3DH.%26aulast%3DWeismann%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DPecchi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Phosphoinositide-3-Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D34%26epage%3D38%26doi%3D10.1021%2Fml1001932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0liruhSf5MCVrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7815</span>– <span class="NLM_lpage">7833</span>, <span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Q.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+Design+of+Phosphoinositide+3-Kinase+%CE%B1+Inhibitors+That+Exhibit+Selectivity+over+the+Phosphoinositide+3-Kinase+%CE%B2+Isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0lh-nICzDm6aTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520Design%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B1%2520Inhibitors%2520That%2520Exhibit%2520Selectivity%2520over%2520the%2520Phosphoinositide%25203-Kinase%2520%25CE%25B2%2520Isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2-4-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5Dimidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0lh-nICzDm6aTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2-4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic Efficiency as an Important Metric in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+Efficiency+as+an+Important+Metric+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lh-nICzDm6aTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520Efficiency%2520as%2520an%2520Important%2520Metric%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Deal, J. G.</span>; <span class="NLM_string-name">Gallego, G. M.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Orr, S. T. M.</span>; <span class="NLM_string-name">Shen, H.</span>; <span class="NLM_string-name">Zehnder, L. R.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrrolopyrimidine Derivatives as PI3Kα Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2015155624A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Chen&author=H.+Cheng&author=J.+G.+Deal&author=G.+M.+Gallego&author=M.+Jalaie&author=J.+C.+Kath&author=S.+T.+M.+Orr&author=H.+Shen&author=L.+R.+Zehnder&title=Dihydropyrrolopyrimidine+Derivatives+as+PI3K%CE%B1+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26atitle%3DDihydropyrrolopyrimidine%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlaeger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tewes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuensch, B.</span></span> <span> </span><span class="NLM_article-title">Novel, One-pot Procedure for the Synthesis of 2-Arylethanol Derivatives</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1067021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1055%2Fs-2008-1067021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=1793-1797&author=T.+Schlaegerauthor=C.+Oberdorfauthor=B.+Tewesauthor=B.+Wuensch&title=Novel%2C+One-pot+Procedure+for+the+Synthesis+of+2-Arylethanol+Derivatives&doi=10.1055%2Fs-2008-1067021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1067021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1067021%26sid%3Dliteratum%253Aachs%26aulast%3DSchlaeger%26aufirst%3DT.%26aulast%3DOberdorf%26aufirst%3DC.%26aulast%3DTewes%26aufirst%3DB.%26aulast%3DWuensch%26aufirst%3DB.%26atitle%3DNovel%252C%2520One-pot%2520Procedure%2520for%2520the%2520Synthesis%2520of%25202-Arylethanol%2520Derivatives%26jtitle%3DSynthesis%26date%3D2008%26volume%3D11%26spage%3D1793%26epage%3D1797%26doi%3D10.1055%2Fs-2008-1067021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Gallego, G. M.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Orr, S. T. M.</span>; <span class="NLM_string-name">Pairish, M. A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidine Derivatives as PI3Kα Inhibitors and their Preparation</span>. <span class="NLM_patent">WO2017009751A1</span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+Chen&author=H.+Cheng&author=G.+M.+Gallego&author=M.+Jalaie&author=J.+C.+Kath&author=S.+T.+M.+Orr&author=M.+A.+Pairish&title=Pyrimidine+Derivatives+as+PI3K%CE%B1+Inhibitors+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26atitle%3DPyrimidine%2520Derivatives%2520as%2520PI3K%25CE%25B1%2520Inhibitors%2520and%2520their%2520Preparation%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubovic, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortsman, J.</span></span> <span> </span><span class="NLM_article-title">Alkaline Phosphatase (EC 3.1.3.1) in Serum Is Inhibited by Physiological Concentrations of Inorganic Phosphate</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">3951</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1210/jc.83.11.3951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1210%2Fjc.83.11.3951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=9814474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaK1cXntlOit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=3951-3957&author=S.+P.+Coburnauthor=J.+D.+Mahurenauthor=M.+Jainauthor=Y.+Zubovicauthor=J.+Wortsman&title=Alkaline+Phosphatase+%28EC+3.1.3.1%29+in+Serum+Is+Inhibited+by+Physiological+Concentrations+of+Inorganic+Phosphate&doi=10.1210%2Fjc.83.11.3951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate</span></div><div class="casAuthors">Coburn, Stephen P.; Mahuren, J. Dennis; Jain, Manas; Zubovic, Yvonne; Wortsman, Jacobo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3951-3957</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Natural and artificial manipulation of tissue nonspecific alk. phosphatase activity indicates that pyrophosphate, phosphoethanolamine, and pyridoxal 5'-phosphate are among the natural substrates for this enzyme.  Although inorg. phosphate has been recognized as a competitive inhibitor of this enzyme for many years, the influence of phosphate on alk. phosphatase activity in serum under physiol. conditions has not been previously reported.  Here, the authors examd. the kinetics of tissue nonspecific alk. phosphatase from bovine kidney and sera from 49 patients with a wide range of endogenous phosphate concns. using pyridoxine 5'-phosphate as a substrate at pH 7.4.  For the bovine kidney enzyme, the Km was 0.42 μM, and the Ki for phosphate was 2.4 μM.  Anal. of the kinetics using pyridoxine 5'-phosphate in undiluted serum from 10 subjects with P in the range of 0.5-2.1 mM and alk. phosphatase activity in the range of 41-165 nmol/min/mL gave ests. for the Km of 56 μM and for the Ki of 540 μM for phosphate.  This indicated that under physiol. conditions alk. phosphatase activity toward pyridoxine 5'-phosphate is reduced ∼50% by the normal phosphate concn. and that it will increase or decrease significantly in response to changes in phosphate concn. within the ranges obsd. clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_g2bgDndbj7Vg90H21EOLACvtfcHk0lg75taIjWPZRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlOit7o%253D&md5=97cecacda1e9f6f14e8bb57d3db191e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1210%2Fjc.83.11.3951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.83.11.3951%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DS.%2BP.%26aulast%3DMahuren%26aufirst%3DJ.%2BD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DZubovic%26aufirst%3DY.%26aulast%3DWortsman%26aufirst%3DJ.%26atitle%3DAlkaline%2520Phosphatase%2520%2528EC%25203.1.3.1%2529%2520in%2520Serum%2520Is%2520Inhibited%2520by%2520Physiological%2520Concentrations%2520of%2520Inorganic%2520Phosphate%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1998%26volume%3D83%26spage%3D3951%26epage%3D3957%26doi%3D10.1210%2Fjc.83.11.3951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span> <span> </span><span class="NLM_article-title">Engineering of an Isolated p110α Subunit of PI3Kα Permits Crystallization and Provides a Platform for Structure-based Drug Design</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1002/pro.2517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1002%2Fpro.2517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=25043846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1332-1340&author=P.+Chenauthor=Y.-L.+Dengauthor=S.+Bergqvistauthor=M.+D.+Falkauthor=W.+Liuauthor=S.+Timofeevskiauthor=A.+Brooun&title=Engineering+of+an+Isolated+p110%CE%B1+Subunit+of+PI3K%CE%B1+Permits+Crystallization+and+Provides+a+Platform+for+Structure-based+Drug+Design&doi=10.1002%2Fpro.2517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design</span></div><div class="casAuthors">Chen, Ping; Deng, Ya-Li; Bergqvist, Simon; Falk, Matthew D.; Liu, Wei; Timofeevski, Sergei; Brooun, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1332-1340</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PI3Kα remains an attractive target for the development of anticancer targeted therapy.  A no. of p110α crystal structures in complex with the nSH2-iSH2 fragment of p85 regulatory subunit have been reported, including a few small mol. co-crystal structures, but the utilization of this crystal form is limited by low diffraction resoln. and a crystal packing artifact that partially blocks the ATP binding site.  Taking advantage of recent data on the functional characterization of the lipid binding properties of p110α, we designed a set of novel constructs allowing prodn. of isolated stable p110α subunit missing the adapter-binding domain and lacking or featuring a modified C-terminal lipid binding motif.  While this protein is not catalytically competent to phosphorylate its substrate PIP2, it retains ligand binding properties as indicated by direct binding studies with a pan-PI3Kα inhibitor.  Addnl., we detd. apo and PF-04691502 bound crystal structures of the p110α (105-1048) subunit at 2.65 and 2.85 Å, resp.  Comparison of isolated p110α(105-1048) with the p110α/p85 complex reveals a high degree of structural similarity, which validates suitability of this catalytically inactive p110α for iterative SBDD.  Importantly, this crystal form of p110α readily accommodates the binding of noncovalent inhibitor by means of a fully accessible ATP site.  The strategy presented here can be also applied to structural studies of other members of PI3KIA family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3QqobJxobLVg90H21EOLACvtfcHk0liDYwJEiW1P7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsb3I&md5=4edd5247eb9e8729dc63d50713fd5314</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpro.2517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2517%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26atitle%3DEngineering%2520of%2520an%2520Isolated%2520p110%25CE%25B1%2520Subunit%2520of%2520PI3K%25CE%25B1%2520Permits%2520Crystallization%2520and%2520Provides%2520a%2520Platform%2520for%2520Structure-based%2520Drug%2520Design%26jtitle%3DProtein%2520Sci.%26date%3D2014%26volume%3D23%26spage%3D1332%26epage%3D1340%26doi%3D10.1002%2Fpro.2517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafidi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHarg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span> <span> </span><span class="NLM_article-title">PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2199</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1158%2F1535-7163.MCT-11-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=21750219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2189-2199&author=J.+Yuanauthor=P.+P.+Mehtaauthor=M.-J.+Yinauthor=S.+Sunauthor=A.+Zouauthor=J.+Chenauthor=K.+Rafidiauthor=Z.+Fengauthor=J.+Nickelauthor=J.+Engebretsenauthor=J.+Hallinauthor=A.+Blasinaauthor=E.+Zhangauthor=L.+Nguyenauthor=M.+Sunauthor=P.+K.+Vogtauthor=A.+McHargauthor=H.+Chengauthor=J.+G.+Christensenauthor=J.+L.+C.+Kanauthor=S.+Bagrodia&title=PF-04691502%2C+a+Potent+and+Selective+Oral+Inhibitor+of+PI3K+and+mTOR+Kinases+with+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-11-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity</span></div><div class="casAuthors">Yuan, Jing; Mehta, Pramod P.; Yin, Min-Jean; Sun, Shaoxian; Zou, Aihua; Chen, Jeffrey; Rafidi, Kristina; Feng, Zheng; Nickel, Jeffrey; Engebretsen, Jon; Hallin, Jill; Blasina, Alessandra; Zhang, Eric; Nguyen, Leslie; Sun, Minghao; Vogt, Peter K.; McHarg, Aileen; Cheng, Hengmiao; Christensen, James G.; Kan, Julie L. C.; Bagrodia, Shubha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2189-2199</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently in human cancer and contributes to resistance to antitumor therapies.  Inhibition of key signaling proteins in the pathway therefore represents a valuable targeting strategy for diverse cancers.  PF-04691502 is an ATP-competitive PI3K/mTOR dual inhibitor, which potently inhibited recombinant class I PI3K and mTOR in biochem. assays and suppressed transformation of avian fibroblasts mediated by wild-type PI3K γ, δ, or mutant PI3Kα.  In PIK3CA-mutant and PTEN-deleted cancer cell lines, PF-04691502 reduced phosphorylation of AKT T308 and AKT S473 (IC50 of 7.5-47 nmol/L and 3.8-20 nmol/L, resp.) and inhibited cell proliferation (IC50 of 179-313 nmol/L).  PF-04691502 inhibited mTORC1 activity in cells as measured by PI3K-independent nutrient stimulated assay, with an IC50 of 32 nmol/L and inhibited the activation of PI3K and mTOR downstream effectors including AKT, FKHRL1, PRAS40, p70S6K, 4EBP1, and S6RP.  Short-term exposure to PF-04691502 predominantly inhibited PI3K, whereas mTOR inhibition persisted for 24 to 48 h.  PF-04691502 induced cell cycle G1 arrest, concomitant with upregulation of p27 Kip1 and redn. of Rb.  Antitumor activity was obsd. in U87 (PTEN null), SKOV3 (PIK3CA mutation), and gefitinib- and erlotinib-resistant non-small cell lung carcinoma xenografts.  In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity.  PF-04691502 has entered phase I clin. trials.  Mol Cancer Ther; 10(11); 2189-99.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQbgF6Nz1KLVg90H21EOLACvtfcHk0liDYwJEiW1P7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7M&md5=d9f8ba9118729c7a9c640ac5f1ae8817</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0185%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DNickel%26aufirst%3DJ.%26aulast%3DEngebretsen%26aufirst%3DJ.%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DBlasina%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMcHarg%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DKan%26aufirst%3DJ.%2BL.%2BC.%26aulast%3DBagrodia%26aufirst%3DS.%26atitle%3DPF-04691502%252C%2520a%2520Potent%2520and%2520Selective%2520Oral%2520Inhibitor%2520of%2520PI3K%2520and%2520mTOR%2520Kinases%2520with%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2189%26epage%3D2199%26doi%3D10.1158%2F1535-7163.MCT-11-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the Reversible Inhibition of Enzyme-catalyzed Reactions by Tight-binding Inhibitors</span>. <i>Biochim. Biophys. Acta, Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(69)90420-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2F0005-2744%2869%2990420-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=4980133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1969&pages=269-286&author=J.+F.+Morrison&title=Kinetics+of+the+Reversible+Inhibition+of+Enzyme-catalyzed+Reactions+by+Tight-binding+Inhibitors&doi=10.1016%2F0005-2744%2869%2990420-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-86</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">A theoretical kinetic study has been undertaken to det. the kinetic characteristics of enzymic reactions that are reversibly inhibited by a substrate analog. at concns. comparable to that of the enzyme.  A general rate equation, that allows for the combination of such a tight-binding inhibitor with one or more enzyme forms of any reaction mechanism, has been derived and shown to be quadratic with sq. and linear terms in υ which represents the true initial steady-state velocity.  From plots of υ against total enzyme concn. at fixed total inhibitor concn., the concn. of enzyme catalytic sites can be detd. irrespective of the nature of the inhibition and the reaction mechanism.  However, plots of υ (or I/υ) against total inhibitor concn. can be used for this purpose only if the dissocn. const. assocd. with the inhibitor is virtually zero.  Particular initial rate equations have been obtained for the cases in which the tight-binding inhibitor gives rise to competitive, noncompetitive, and uncompetitive inhibition with respect to one of the substrates of a bireactant mechanism.  From these equations it has been deduced that, in the presence of inhibitor, plots of I/υ against the reciprocals of the substrate concns. yield families of concave-down, nonrectangular hyperbolas.  The difficulties assocd. with the detn. of inhibition consts. for tight-binding inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4s_N2iV3CLVg90H21EOLACvtfcHk0liDYwJEiW1P7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D&md5=74d467477385488dfbb053358534ada6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2869%2990420-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252869%252990420-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26atitle%3DKinetics%2520of%2520the%2520Reversible%2520Inhibition%2520of%2520Enzyme-catalyzed%2520Reactions%2520by%2520Tight-binding%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Enzymol.%26date%3D1969%26volume%3D185%26spage%3D269%26epage%3D286%26doi%3D10.1016%2F0005-2744%2869%2990420-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greco, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakala, M. T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Methods for Estimating the Dissociation Constant of Tight Binding Enzyme Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">12104</span>– <span class="NLM_lpage">12109</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=10.1016%2FS0021-9258%2819%2986435-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=500698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;key=1%3ACAS%3A528%3ADyaL3cXitlem" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=12104-12109&author=W.+R.+Grecoauthor=M.+T.+Hakala&title=Evaluation+of+Methods+for+Estimating+the+Dissociation+Constant+of+Tight+Binding+Enzyme+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors</span></div><div class="casAuthors">Greco, William R.; Hakala, Maire T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12104-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A Monte Carlo simulation was used to compare 11 methods for estg. the Ki of tight binding enzyme inhibitors.  The methods were evaluated for both accuracy and precision.  Parameters were chosen to simulate the inhibition of dihydrofolate reductase by methotrexate, using dihydrofolate as substrate.  These parameters were: Ki, 100 pM; turnover no., 500/min; molar equivalency of enzyme, 400 pM/unit; dihydrofolate concn., 50 μM; and Km, 0.5 μM.  Inputs of total enzyme concn. (Et) and total inhibitor concn. (It) were chosen to keep the value of Et/Ki between 4 and 20 and to allow estn. of the concn. of the inhibitor causing 50% inhibition (I50) at each Et.  Four types of error were introduced into the simulated data: small abs., large abs., small relative, and large relative error.  Computer methods based on the equations of W. W. Ackermann and V. R. Potter (1949) and J. F. Morrison (1969) which utilized nonlinear regression, proved to be significantly more precise than the methods which would require the use of only pencil and paper.  Based on these findings a review of the published Ki values for the inhibition of dihydrofolate reductase by methotrexate is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqahqxjd5cipLVg90H21EOLACvtfcHk0lh6IyM-eC-zhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXitlem&md5=b238cb9e286f95a348838d70cb9908f1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2986435-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252986435-9%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DW.%2BR.%26aulast%3DHakala%26aufirst%3DM.%2BT.%26atitle%3DEvaluation%2520of%2520Methods%2520for%2520Estimating%2520the%2520Dissociation%2520Constant%2520of%2520Tight%2520Binding%2520Enzyme%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D12104%26epage%3D12109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71','PDB','7K71'); return false;">PDB: 7K71</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O','PDB','7K6O'); return false;">PDB: 7K6O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N','PDB','7K6N'); return false;">PDB: 7K6N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M','PDB','7K6M'); return false;">PDB: 7K6M</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i38"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01652">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_72112"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01652?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01652</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Kinase selectivity assays; kinase selectivity data for compound <b>1</b>; biological data with standard deviation and number of tests for all of the examples in <a class="ref showTableEvent internalNav" href="#tbl1">Tables <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" href="#tbl3">3</a>–<a class="ref showTableEvent internalNav" href="#tbl5">5</a>; cellular potency comparison between <b>1</b> and alpelisib with standard deviation and number of tests; HPLC traces for lead compounds; modeled binding mode of <b>11</b> in PI3Kβ; modeled binding mode of <b>1</b> in mTOR; synthetic procedures for compounds <b>5</b>–<b>10</b>, <b>12</b>–<b>18</b>, and <b>28</b>–<b>34</b>; enzymatic hydrolysis of <b>40</b> to <b>1</b> in vitro studies and graphs; in vivo rat PK and TK studies and graphs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_001.pdf">jm0c01652_si_001.pdf (749.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01652/suppl_file/jm0c01652_si_002.csv">jm0c01652_si_002.csv (2.54 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6M">7K6M</a> for compound <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K71">7K71</a> for compound <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6O">7K6O</a> for compound <b>10</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K6N">7K6N</a> for compound <b>11</b>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01652&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01652%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01652" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991d3f8f553d66","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
